<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006960</article-id><article-id pub-id-type="pmc">PMC11860432</article-id><article-id pub-id-type="doi">10.3390/v17020206</article-id><article-id pub-id-type="publisher-id">viruses-17-00206</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Viral Suppression and HIV Drug Resistance Among Patients on Second-Line Antiretroviral Therapy in Selected Health Facility in Ethiopia</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5248-5036</contrib-id><name><surname>Zealiyas</surname><given-names>Kidist</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1987-6996</contrib-id><name><surname>Gebreegziabxier</surname><given-names>Atsbeha</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Getaneh</surname><given-names>Yimam</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kidane</surname><given-names>Eleni</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6080-0200</contrib-id><name><surname>Woldesemayat</surname><given-names>Belete</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Yizengaw</surname><given-names>Ajanaw</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6117-1589</contrib-id><name><surname>Gutema</surname><given-names>Gadisa</given-names></name><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Adane</surname><given-names>Sisay</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Yimer</surname><given-names>Mengistu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Yilma</surname><given-names>Amelework</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5526-3340</contrib-id><name><surname>Tadele</surname><given-names>Sisay</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3985-8181</contrib-id><name><surname>Sasinovich</surname><given-names>Sviataslau</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-viruses-17-00206" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Medstrand</surname><given-names>Patrik</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-viruses-17-00206" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9702-0216</contrib-id><name><surname>Arimide</surname><given-names>Dawit Assefa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-17-00206" ref-type="aff">1</xref><xref rid="af2-viruses-17-00206" ref-type="aff">2</xref><xref rid="c1-viruses-17-00206" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Hizi</surname><given-names>Amnon</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00206"><label>1</label>Infectious Diseases Research Directorate, Ethiopian Public Health Institute, Addis Ababa 1242, Ethiopia; <email>kzealiyas@gmail.com</email> (K.Z.); <email>atsbehag@gmail.com</email> (A.G.); <email>yimamgetaneh@gmail.com</email> (Y.G.); <email>elikid2003@gmail.com</email> (E.K.); <email>beleteweldesemeyat@gmail.com</email> (B.W.); <email>ajanawy19@gmail.com</email> (A.Y.); <email>gadissagutema@gmail.com</email> (G.G.); <email>sisay0229@gmail.com</email> (S.A.); <email>mengeyimer12@gmail.com</email> (M.Y.); <email>sameleworkyilema@yahoo.com</email> (A.Y.); <email>sisay75t@gmail.com</email> (S.T.)</aff><aff id="af2-viruses-17-00206"><label>2</label>Department of Translational Medicine, Lund University, 22185 Lund, Sweden; <email>sviataslau.sasinovich@med.lu.se</email> (S.S.); <email>patrik.medstrand@med.lu.se</email> (P.M.)</aff><author-notes><corresp id="c1-viruses-17-00206"><label>*</label>Correspondence: <email>dawit.assefa@med.lu.se</email>; Tel.: +46-737540049</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>206</elocation-id><history><date date-type="received"><day>27</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>HIV drug resistance (HIVDR) presents a significant challenge to antiretroviral therapy (ART) success, particularly in resource-limited settings like Ethiopia. This cross-sectional study investigated viral suppression rates and resistance patterns among patients on second-line ART across 28 Ethiopian health facilities. Blood samples collected from 586 participants were analyzed to measure CD4 count and viral load and assess HIVDR in patients experiencing virological failure (VF) (viral load &#x02265; 1000 copies/mL). Demographic and clinical data were analyzed using logistic regression to identify factors associated with VF. Results showed that 13.82% of participants experienced VF, with 67.57% of genotyped samples exhibiting at least one drug resistance mutation. Resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) was detected in 48.64%, 64.86%, and 18.92% of cases, respectively. Dual-class resistance was identified in 48.64% of patients, while triple-class resistance was detected in 18.92%. VF was more likely among students and those with CD4 counts below 200 cells/mm&#x000b3;, but less likely in patients on second-line treatment for 12 months or more. Our findings highlight a substantial HIVDR burden among patients on second-line ART with VF, emphasizing the need for comprehensive HIV care, including adherence support, regular viral load monitoring, and HIVDR testing.</p></abstract><kwd-group><kwd>antiretroviral therapy</kwd><kwd>HIV-1 drug resistance</kwd><kwd>viral suppression</kwd><kwd>second-line regimen</kwd><kwd>adherence</kwd><kwd>Ethiopia</kwd></kwd-group><funding-group><award-group><funding-source>WHO Ethiopia Country Office and the Ethiopian Public Health Institute (EPHI)</funding-source><award-id>WHO-HIVDR-5385</award-id></award-group><award-group><funding-source>Swedish Research Council</funding-source><award-id>2020-02344</award-id></award-group><award-group><funding-source>&#x000d6;sterlund Foundation</funding-source></award-group><award-group><funding-source>Medical Faculty of Lund</funding-source></award-group><funding-statement>This research was supported by the WHO Ethiopia Country Office and the Ethiopian Public Health Institute (EPHI) under WHO-HIVDR-5385 and by the Swedish Research Council (grant number 2020-02344), the &#x000d6;sterlund Foundation, and a donation through the Medical Faculty of Lund.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00206"><title>1. Introduction</title><p>Antiretroviral therapy (ART) roll-out has significantly improved the prognosis of HIV-infected individuals, transforming HIV from a fatal disease into a manageable chronic condition and potentially preventable condition [<xref rid="B1-viruses-17-00206" ref-type="bibr">1</xref>,<xref rid="B2-viruses-17-00206" ref-type="bibr">2</xref>]. However, the effectiveness of ART is increasingly threatened by the emergence and transmission of HIV drug resistance (HIVDR) [<xref rid="B3-viruses-17-00206" ref-type="bibr">3</xref>,<xref rid="B4-viruses-17-00206" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00206" ref-type="bibr">5</xref>]. This challenge is particularly significant in resource-limited settings where routine viral load (VL) and HIVDR monitoring are not consistently implemented due to financial, infrastructural, and logistical constraints. The lack of regular VL testing can result in undetected treatment failure for prolonged periods, leading to the accumulation of drug resistance mutations (DRMs) and undermining the effectiveness of both the current and future treatment options [<xref rid="B3-viruses-17-00206" ref-type="bibr">3</xref>,<xref rid="B5-viruses-17-00206" ref-type="bibr">5</xref>]. The absence of resistance testing in HIV treatment management can lead to premature switching to more costly and complex second-line regimens when first-line treatments could still be effective with improved adherence support. It may also result in the selection of suboptimal regimens that foster further resistance evolution, compromising the efficacy of second-line therapy and leaving patients with limited alternatives for long-term HIV management [<xref rid="B4-viruses-17-00206" ref-type="bibr">4</xref>,<xref rid="B6-viruses-17-00206" ref-type="bibr">6</xref>]. At the population level, insufficient monitoring can lead to the increased transmission of HIVDR strains, which complicates treatment strategies for newly infected individuals and potentially undermines the overall effectiveness of ART programs [<xref rid="B5-viruses-17-00206" ref-type="bibr">5</xref>,<xref rid="B6-viruses-17-00206" ref-type="bibr">6</xref>].</p><p>Ethiopia is one of the Sub-Saharan African countries most affected by the HIV-1 epidemic. In Ethiopia, ART is delivered through a public health approach that utilizes standardized first- and second-line treatment regimens along with simplified laboratory monitoring, which includes at least one viral load test annually. At the time of study enrollment, Ethiopia&#x02019;s national ART guidelines recommended first-line regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs)&#x02014;tenofovir (TDF) with lamivudine (3TC)&#x02014;combined with a non-nucleoside reverse transcriptase inhibitor (NNRTI) such as efavirenz (EFV) and nevirapine (NVP). However, the guidelines have evolved over time to incorporate newer, more effective drug combinations. Notably, dolutegravir (DTG), an integrase strand transfer inhibitor (INSTI), has been adopted as a preferred option in first-line regimens [<xref rid="B7-viruses-17-00206" ref-type="bibr">7</xref>]. For second-line regimens, the guidelines advised the use of two NRTIs (such as zidovudine (ZDV) or abacavir (ABC) with 3TC) along with a ritonavir-boosted protease inhibitor, either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) [<xref rid="B7-viruses-17-00206" ref-type="bibr">7</xref>].</p><p>At the initiation of this study in 2017, Ethiopia had approximately 414,854 adults receiving ART out of an estimated 610,000 adults living with HIV, according to data from the Ethiopian Federal Ministry of Health. Of the patients receiving ART, approximately 6552 were on protease inhibitor/ritonavir (PI/r)-based second-line regimens [<xref rid="B7-viruses-17-00206" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00206" ref-type="bibr">8</xref>]. Despite significant progress in scaling up ART in Ethiopia, routine virological monitoring and HIVDR testing are not yet standard practices in HIV care. As the number of individuals initiating first-line ART continues to grow, there is an anticipated increase in HIVDR and treatment failure, leading to a significant number of patients transitioning to second-line regimens [<xref rid="B3-viruses-17-00206" ref-type="bibr">3</xref>,<xref rid="B4-viruses-17-00206" ref-type="bibr">4</xref>]. Patients on second-line ART represent a unique population with histories of ART failure, longer durations of HIV infection, and a higher potential for accumulating HIVDRMs [<xref rid="B9-viruses-17-00206" ref-type="bibr">9</xref>]. However, there is a notable lack of data on long-term outcomes and HIVDR patterns among patients on second-line regimens in Ethiopia. This study aims to assess the rate of virological failure (VF), the prevalence of HIVDR, and identify the factors associated with VF among patients on second-line ART in Ethiopia.</p></sec><sec sec-type="methods" id="sec2-viruses-17-00206"><title>2. Methods</title><sec id="sec2dot1-viruses-17-00206"><title>2.1. Study Design</title><p>In 2017, a cross-sectional study was conducted as part of a national survey to assess the prevalence of HIVDR in Ethiopia. This study included 28 ART sites, selected using probability proportional to size (PPS) sampling to ensure representation across various geographic regions and clinic sizes [<xref rid="B10-viruses-17-00206" ref-type="bibr">10</xref>]. After selecting the clinics, we included all consecutive adults (&#x02265;18 years) who had been receiving second-line ART for at least six months during the study period based on a predetermined sample size that factored in the proportion of patients on second-line regimens at each facility. Written informed consent was obtained from all participants. Blood samples (10 mL) were collected via venipuncture from each participant for CD4+ T-cell counts, viral load measurements, and HIVDR genotyping. Basic demographic and clinical information were also collected using a standardized questionnaire. Plasma samples were transported on dry ice to the Ethiopian Public Health Institute (EPHI) for viral load testing and long-term storage at &#x02212;80 &#x000b0;C. VL was quantified using the Abbott RealTime HIV-1 assay (Abbott Molecular Inc., Des Plaines, IL, USA). Samples with VL &#x02265; 1000 copies/mL were shipped to the National Institute of Respiratory Diseases (INER) laboratory in Mexico for HIVDR testing.</p></sec><sec id="sec2dot2-viruses-17-00206"><title>2.2. HIV-1 Sequencing</title><p>The HIVDR testing was performed at a WHO-designated laboratory in Mexico City, according to the WHO/HIV ResNet Laboratory Operational Framework [<xref rid="B11-viruses-17-00206" ref-type="bibr">11</xref>]. Briefly, HIV RNA was extracted from 1 mL of plasma using the QIAamp Viral RNA Kit (QIAGEN, Valencia, CA, USA). Subsequently, the protease-reverse transcriptase (PR-RT) regions were amplified using validated in-house protocols [<xref rid="B12-viruses-17-00206" ref-type="bibr">12</xref>]. The purified PCR fragments were then sequenced using the BigDye technology on the ABI Prism 3730 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Sequence assembly and editing were performed using the RECallV 2.0 HIV-1 sequencing analysis tool (University of British Columbia, Vancouver, BC, Canada) [<xref rid="B13-viruses-17-00206" ref-type="bibr">13</xref>]. Sequence quality control was performed using the WHO tool <uri xlink:href="https://sequenceqc-dev.bccfe.ca/who_qc">https://sequenceqc-dev.bccfe.ca/who_qc</uri> (accessed on 16 March 2024) and the Quality Control program of the Los Alamos HIV sequence database <uri xlink:href="https://www.hiv.lanl.gov/">https://www.hiv.lanl.gov/</uri> (accessed on 16 March 2024).</p></sec><sec id="sec2dot3-viruses-17-00206"><title>2.3. HIV-1 Drug Resistance Analysis</title><p>The HIVDR analysis was conducted using the Stanford HIV Drug Resistance Database (HIVdB v9.1) (<uri xlink:href="https://hivdb.stanford.edu/hivdb/by-mutations">https://hivdb.stanford.edu/hivdb/by-mutations</uri>, accessed on 29 June 2023). The prevalence of mutation patterns and their frequencies were calculated for each of the following drug classes: NRTIs, NNRTIs, and PIs. Additionally, an HIVDR susceptibility analysis was performed using the HIVdb algorithm, which assigns a drug penalty score for each antiretroviral drug. The cumulative scores were then used to classify the level of resistance into four categories: susceptible (score &#x0003c; 15), low-level resistance (score 15&#x02013;29), intermediate resistance (score 30&#x02013;59), or high-level resistance (score &#x02265; 60).</p></sec><sec id="sec2dot4-viruses-17-00206"><title>2.4. HIV-1 Subtype Determination</title><p>The HIV-1 subtyping was carried out using the online automated subtyping tools REGA v3.0 [<xref rid="B14-viruses-17-00206" ref-type="bibr">14</xref>], COMET [<xref rid="B15-viruses-17-00206" ref-type="bibr">15</xref>], and the jumping profile Hidden Markov Model (jpHMM) [<xref rid="B16-viruses-17-00206" ref-type="bibr">16</xref>,<xref rid="B17-viruses-17-00206" ref-type="bibr">17</xref>]. Subtyping was further validated by maximum likelihood (ML) phylogenetic tree analysis with the reference sequences from HIV-1 subtypes (A&#x02013;K) and recombinant viruses, which were downloaded from the Los Alamos database (<uri xlink:href="http://www.hiv.lanl.gov">http://www.hiv.lanl.gov</uri>, accessed on 3 June 2023). Multiple sequence alignment was performed using MAFFT version 7 [<xref rid="B18-viruses-17-00206" ref-type="bibr">18</xref>] and then manually edited using BioEdit V7.0.9.0 to achieve a perfect codon alignment [<xref rid="B19-viruses-17-00206" ref-type="bibr">19</xref>,<xref rid="B20-viruses-17-00206" ref-type="bibr">20</xref>]. The ML tree topology was constructed using the online version of PhyML v3.0 [<xref rid="B21-viruses-17-00206" ref-type="bibr">21</xref>] with the GTR + I + &#x00393; nucleotide-substitution model (utilizing the estimated proportion of invariable sites and four gamma categories) [<xref rid="B16-viruses-17-00206" ref-type="bibr">16</xref>]. A heuristic tree search was conducted using the SPR branch-swapping algorithm. Branch support was evaluated with the approximate likelihood ratio test (aLRT-SH, Shimodaira Hasegawa-like) [<xref rid="B22-viruses-17-00206" ref-type="bibr">22</xref>]. Clusters were defined as monophyletic clades with aLRT-SH support &#x02265; 0.9 [<xref rid="B16-viruses-17-00206" ref-type="bibr">16</xref>]. The subtype-resolved ML phylogeny trees were visualized using the FigTree v1.4.0 program [<xref rid="B23-viruses-17-00206" ref-type="bibr">23</xref>]. Sequences forming clusters with the reference sequences of the same subtype were assigned to that subtype.</p></sec><sec id="sec2dot5-viruses-17-00206"><title>2.5. Data Quality Management</title><p>Data quality assurance was rigorously maintained through a multi-step process. Every tenth entry of the retrospectively collected data was cross-checked, and all case and laboratory report forms were verified against the source data to ensure accuracy. Following this initial verification, the data were independently entered into Epi-Info V6.04 by two separate data clerks. This software was equipped with check programs to prevent the entry of erroneous data, adding an additional layer of quality control. Furthermore, manual consistency checks were performed to further enhance data integrity. Once these quality control measures were completed, the data were exported to SPSS v.26 for comprehensive analysis.</p></sec><sec id="sec2dot6-viruses-17-00206"><title>2.6. Statistical Analysis</title><p>Descriptive statistics were used to summarize demographic and clinical characteristics. The prevalence of VF (defined as having a viral load &#x02265; 1000 copies/mL) and acquired HIVDR was calculated, and associations between clinical characteristics and virological outcomes were assessed using logistic regression models. Different patient-related characteristics, including socio-demographic, clinical, immunological, and virological characteristics, were included in the analysis. Initially, variables were examined individually, and those demonstrating an association with VF at a <italic toggle="yes">p</italic>-value of &#x0003c; 0.2 were included in a multivariable logistic regression model. Prior to conducting the multivariable analysis, correlation analysis was performed to evaluate potential multicollinearity among variables, and no multicollinearity was detected. In the final multivariable model, predictors with <italic toggle="yes">p</italic>-values &#x0003c; 0.05 were considered statistically significant. Crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were reported to quantify the strength of the associations.</p></sec><sec id="sec2dot7-viruses-17-00206"><title>2.7. Ethical Considerations</title><p>The study protocol received approval from the Scientific and Ethical Research Office of the Ethiopian Public Health Institute (EPHI) and the Institutional Review Board of the Ethiopian Ministry of Science and Technology.</p></sec></sec><sec sec-type="results" id="sec3-viruses-17-00206"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-viruses-17-00206"><title>3.1. Demographic Characteristics of Study Participants</title><p>A total of 586 participants were included in this study. Females comprised a greater portion of the sample at 54.44%, compared to males at 45.56%. The largest age group was individuals aged between 35 and 44 years (41.81%), followed by those aged 25 to 34 years (27.30%), over 45 years (24.91%), and 18 to 24 years (5.97%). Most participants resided in urban areas (84.47%), while 15.53% lived in rural regions. Regarding marital status, 39.93% were in monogamous marriages, 21.84% were unmarried, 19.80% were divorced, 9.39% were widowed, and 9.04% were in polygamous marriages. Educational attainment varied as follows: 44.20% had primary education, 23.21% had secondary education, 12.63% had college or university education, and 19.97% had no formal education. Occupational statuses were diverse, with housewives constituting 18.09%, government employees 17.06%, merchants 16.38%, unemployed individuals 15.36%, and students 4.27%. Other occupations, including drivers and various other jobs, accounted for 24.74% of the participants (<xref rid="viruses-17-00206-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3dot2-viruses-17-00206"><title>3.2. ART Regimen and Clinical Characteristics of Patients on Second-Line Therapy</title><p>At the initiation of first-line ART, the most frequently prescribed regimen was AZT + 3TC + NVP, accounting for 26.79% of patients. This was followed by TDF + 3TC + EFV at 18.09%. Other combinations included D4T + 3TC + NVP (15.19%) and TDF + 3TC + NVP (14.33%). Less commonly used regimens were AZT + 3TC + EFV (12.46%), D4T + 3TC + EFV (5.12%), ABC + 3TC + NVP (6.14%), and ABC + 3TC + EFV (1.88%). The majority of patients (69.97%) switched after more than 91 months on first-line ARVs, while smaller proportions switched earlier as follows: 1.71% before 30 months, 7.17% between 31 and 60 months, and 21.16% between 61 and 90 months.</p><p>The most commonly prescribed second-line regimens were TDF + 3TC + ATV/r, used by 44.20% of participants, followed by ABC + 3TC + ATV/r (19.45%) and AZT + 3TC + ATV/r (17.58%). Smaller proportions were on TDF + 3TC + LPV/r (9.73%), AZT + 3TC + LPV/r (5.63%), and ABC + 3TC + LPV/r (3.41%). The duration of therapy on the second-line regimen varied as follows: the majority (55.80%) had been on second-line therapy for 16&#x02013;48 months, 29.69% for 6&#x02013;15 months, and 14.51% for over 49 months. At the initiation of ART, all participants had a CD4 count below 200 cells/mm<sup>3</sup>. By the time they switched to second-line treatment, 70.30% still had a CD4 count below 200 cells/mm<sup>3</sup>. However, at the time of this study, 71.00% of participants had achieved CD4 counts above 200 cells/mm<sup>3</sup>, while 29.00% still had CD4 counts below this threshold. Viral suppression, defined as an RNA viral load below 1000 copies/mL, was observed in 86.18% of participants, as shown in <xref rid="viruses-17-00206-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec3dot3-viruses-17-00206"><title>3.3. HIV Drug Resistance Mutation Profile</title><p>Among the 81 (13.82%) participants experiencing VF, genotyping was successfully performed for 37 individuals. Of these, 25 participants (67.56%) harbored at least one DRM. Dual-class DRMs, affecting both NRTI and NNRTI and/or PI classes, were observed in 18 participants (48.64%), while triple-class DRMs (involving PI, NRTI, and NNRTI) were identified in 7 participants (18.92%) (see <xref rid="viruses-17-00206-f001" ref-type="fig">Figure 1</xref>).</p><p>NRTI-associated DRMs were detected in 18 participants (48.64%), with M184V being the most frequent NRTI mutation, occurring in 22.86% of patients. Thymidine analogue mutations (TAMs) were detected in 38.57% of patients, with specific mutations, including T215Y/V (10.00%), K70E (8.57%), D67N (8.57%), and K219E (7.14%), while K65R and Y115F were found in 7.14% and 8.57%, respectively. NNRTI-associated DRMs were detected in 18 patients (48.64%). The most predominant NNRTI-associated mutations detected included K103N (18.87%), Y181C (13.21%), and G190A (13.21%). Additional mutations such as H221Y (9.43%), V106I/M (5.66%), V108I (5.66%), A98G (7.55%), and L100I (5.66%) were also detected. PI-associated DRMs were identified in 7 patients (18.92%), with the V82A mutation being the most prevalent, observed in 29.41% of cases. The I54V and M46I mutations were each detected in 23.53% of participants, while I50L (11.76%), L90M (5.88%), and N88S (5.88%) mutations were also observed (<xref rid="viruses-17-00206-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3dot4-viruses-17-00206"><title>3.4. Factors Associated with Virological Failure</title><p>Although various factors were examined, occupation, duration on second-line ART, and current CD4 count were identified as factors associated with second-line ART VF. Among occupational groups, students demonstrated a markedly higher likelihood of experiencing VF, with an adjusted odds ratio (AOR) of 6.14 (95% CI: 1.93&#x02013;19.48) compared to government employees, the reference group. Other occupations, including drivers (AOR = 2.10, 95% CI: 0.61&#x02013;7.20), housewives (AOR = 1.02, 95% CI: 0.33&#x02013;3.19), unemployed individuals (AOR = 1.67, 95% CI: 0.65&#x02013;4.31), and those in the &#x0201c;other&#x0201d; category (AOR = 1.57, 95% CI: 0.67&#x02013;3.68), did not show statistically significant associations. The duration of second-line ART was another critical factor associated with VF. Participants who had been on second-line ART for over 12 months had a significantly lower likelihood of virological failure (AOR = 0.52, 95% CI: 0.28&#x02013;0.97) compared to those on ART for less than 12 months. Additionally, current CD4 count emerged as a significant determinant of outcomes. Participants with a current CD4 count of less than 200 cells/mm&#x000b3; were more likely to experience VF (AOR = 2.55, 95% CI: 1.52&#x02013;4.28) compared to those with a CD4 count at or above 200 cells/mm<sup>3</sup> (<xref rid="viruses-17-00206-t004" ref-type="table">Table 4</xref>).</p></sec><sec id="sec3dot5-viruses-17-00206"><title>3.5. HIV Drug Resistance Susceptibility Testing</title><p>Our antiretroviral drug resistance analysis reveals varying degrees of susceptibility across the three primary ARV classes (NRTIs, NNRTIs, and PIs). Among NRTIs, drugs like AZT and TDF showed higher susceptibility rates at 78.38% and 62.16%, respectively, while drugs like emtricitabine (FTC) and 3TC had significant resistance, with 43.24% exhibiting high levels of resistance. Drugs like D4T and DDI had 59.46% susceptibility, with a notable portion (24.32% and 27.03%, respectively) having high resistance. Among NNRTIs, DOR and ETR had 54.05% susceptibility, with high-level resistance in 8.11% of samples. EFV and NVP showed lower susceptibility rates of 35.14%, accompanied by high-level resistance in 48.65% and 59.46% of samples, respectively. RPV exhibited 51.35% susceptibility, while high-level resistance was observed in 37.84% of samples. PIs generally maintained high levels of susceptibility. DRV was fully susceptible (100%), while ATV demonstrated susceptibility in 81.08% of samples and high-level resistance in 16.22%. FPV, IDV, LPV, NFV, and SQV exhibited susceptibility rates of 83.78% to 86.49%, with high-level resistance detected in 5.41% to 13.51% of samples. TPV showed 86.49% susceptibility, with no case of high-level resistance (<xref rid="viruses-17-00206-t005" ref-type="table">Table 5</xref>).</p></sec><sec id="sec3dot6-viruses-17-00206"><title>3.6. Maximum-likelihood Phylogenetic Tree</title><p>The phylogenetic tree in <xref rid="viruses-17-00206-f002" ref-type="fig">Figure 2</xref> comprises 459 sequences, including 37 Ethiopian sequences and 422 reference sequences for HIV-1 subtypes (A&#x02013;K) and circulating recombinant forms, which were downloaded from the HIV-1 LANL database. An ML tree was constructed using the online version of PhyML v 3.0. In the figure, the reference sequences from the Los Alamos National Laboratory are shown in black. Ethiopian sequences clustering with the HIV-1 subtype C reference sequence are depicted in blue, while non-subtype C Ethiopian sequences are shown in pink. Phylogenetic analysis of the sequences showed that 94.59% (35 out of 37) clustered with HIV-1 subtype C. The remaining two sequences, accounting for 2.70% each, were identified as non-subtype C, specifically subtype B, and a recombinant form of subtypes D and A1 (see <xref rid="viruses-17-00206-f002" ref-type="fig">Figure 2</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-17-00206"><title>4. Discussions</title><p>This study provides the first national data on viral suppression and HIVDR among patients on second-line ART in selected health facilities in Ethiopia. Our findings showed that 13.82% of patients on second-line ART experienced VF, defined as a VL &#x02265; 1000 copies/mL. Notably, 32.43% of study participants did not harbor any DRMs, suggesting that poor adherence to treatment may be the primary cause of VF in these cases. Among patients with VF, 67.57% exhibited at least one class of DRMs, with 48.64% showing dual-class DRMs and 18.921% displaying triple-class DRMs. The low PI-associated DRMs (18.92%) and high susceptibility to drugs like darunavir, atazanavir, and lopinavir suggest that PI-based regimens remain an effective backbone for second-line treatments in Ethiopia if adherence issues are addressed. We also identified risk factors for VF, including being a student (AOR = 6.14; 95% CI: 1.93&#x02013;19.48), shorter duration on second-line treatment (less than 12 months, AOR&#x02009;=&#x02009;0.52; 95% CI: 0.28&#x02013;0.97), and a CD4 count below 200 cells/mm&#x000b3; (AOR = 2.55, 95% CI: 1.52&#x02013;4.28).</p><p>Our study showed that 13.82% of patients on second-line antiretroviral therapy (ART) experienced VF (viral load &#x02265;1000 copies/mL). This finding is consistent with VF rates reported in several other African countries, including Tanzania, Rwanda, Uganda, South Africa, and Ethiopia, where rates ranged from 12% to 41% [<xref rid="B24-viruses-17-00206" ref-type="bibr">24</xref>,<xref rid="B25-viruses-17-00206" ref-type="bibr">25</xref>,<xref rid="B26-viruses-17-00206" ref-type="bibr">26</xref>,<xref rid="B27-viruses-17-00206" ref-type="bibr">27</xref>,<xref rid="B28-viruses-17-00206" ref-type="bibr">28</xref>,<xref rid="B29-viruses-17-00206" ref-type="bibr">29</xref>,<xref rid="B30-viruses-17-00206" ref-type="bibr">30</xref>,<xref rid="B31-viruses-17-00206" ref-type="bibr">31</xref>]. A systematic review and meta-analysis focusing on patients undergoing second-line ART regimens in resource-limited settings further corroborated our results, demonstrating cumulative VF rates between 21.8% and 38.0% [<xref rid="B25-viruses-17-00206" ref-type="bibr">25</xref>]. Our findings, along with those from other studies, underscore the persistent challenge of maintaining viral suppression in patients on second-line therapy across various resource-limited settings.</p><p>Among our study participants, 32.4% did not harbor any DRMs, suggesting that poor adherence to treatment may be the primary cause of VF. This is consistent with previous research in resource-limited settings, which revealed that 33&#x02013;67% of patients on second-line PI-based regimens with VF had no major DRMs, suggesting adherence issues rather than drug resistance as the primary cause of failure [<xref rid="B10-viruses-17-00206" ref-type="bibr">10</xref>,<xref rid="B24-viruses-17-00206" ref-type="bibr">24</xref>,<xref rid="B29-viruses-17-00206" ref-type="bibr">29</xref>,<xref rid="B32-viruses-17-00206" ref-type="bibr">32</xref>,<xref rid="B33-viruses-17-00206" ref-type="bibr">33</xref>]. For example, among patients with VF, 37% in Rwanda [<xref rid="B29-viruses-17-00206" ref-type="bibr">29</xref>], 58.5% in Namibia [<xref rid="B10-viruses-17-00206" ref-type="bibr">10</xref>], and 33% in South Africa [<xref rid="B32-viruses-17-00206" ref-type="bibr">32</xref>] did not harbor any DRMs. Identified risk factors for second-line failure include suboptimal adherence, prior exposure to non-standard regimens, and pre-existing PI resistance [<xref rid="B34-viruses-17-00206" ref-type="bibr">34</xref>,<xref rid="B35-viruses-17-00206" ref-type="bibr">35</xref>]. However, it also raises concerns that some patients may have been prematurely switched to second-line regimens without resistance testing, underscoring the need for resistance testing to ensure optimal treatment decisions.</p><p>Among patients experiencing VF, a significant proportion demonstrated complex resistance patterns. Dual-class DRMs affecting both NRTI and NNRTI classes and/or protease inhibitors were identified in 48.64% of patients. Even more concerning was the presence of triple-class DRMs in 18.92% of cases, involving mutations across all the following three major drug classes: PIs, NRTIs, and NNRTIs. These results are consistent with previous studies in resource-limited settings, where dual-class resistance in patients on second-line ART was found in 40% to 60% of cases [<xref rid="B29-viruses-17-00206" ref-type="bibr">29</xref>,<xref rid="B36-viruses-17-00206" ref-type="bibr">36</xref>]. Furthermore, the observed rate of triple-class resistance (18.92%) in this cohort closely aligns with findings from other studies in sub-Saharan Africa, where 22% of participants experiencing failure on second-line therapy in routine care settings also showed triple-class resistance [<xref rid="B36-viruses-17-00206" ref-type="bibr">36</xref>]. However, this rate is lower than that reported in a study from India, which showed that 53% of patients harbored triple-class resistance [<xref rid="B36-viruses-17-00206" ref-type="bibr">36</xref>]. The findings from this study, along with evidence from prior research, highlight a persistent and widespread issue of HIVDR among patients on second-line ART across various resource-constrained environments. The high prevalence of dual- and triple-class DRMs observed highlights the significant challenges in managing second-line ART failures in these settings. Such multi-class resistance substantially limits future treatment options, potentially necessitating the use of third-line regimens that are typically more expensive and less readily available. These results emphasize the critical need for enhanced viral load monitoring, resistance testing, and improved access to third-line ART in Ethiopia and similar resource-limited contexts [<xref rid="B37-viruses-17-00206" ref-type="bibr">37</xref>,<xref rid="B38-viruses-17-00206" ref-type="bibr">38</xref>]. Additionally, our findings underscore the importance of assessing and supporting medication adherence, as poor adherence remains a major contributor to VF [<xref rid="B29-viruses-17-00206" ref-type="bibr">29</xref>].</p><p>We observed a 48.64% prevalence of NRTI-associated DRMs, with the most common being M184V and TAMs, present in 22.86% and 38.57% of patients, respectively. M184V is known to emerge rapidly in patients receiving 3TC or FTC, which are common components of first-line regimens [<xref rid="B39-viruses-17-00206" ref-type="bibr">39</xref>,<xref rid="B40-viruses-17-00206" ref-type="bibr">40</xref>]. The prevalence of TAMs (T215Y/V, K70E, D67N, and K219E) is particularly concerning, as these mutations accumulate over time and can confer cross-resistance to multiple NRTIs, significantly impacting the effectiveness of NRTI-based regimens [<xref rid="B39-viruses-17-00206" ref-type="bibr">39</xref>]. Additionally, the K65R mutation, detected in 7.14% of patients, raises additional concern due to its association with broad resistance, especially to TDF and ABC, which are critical components of second-line regimens in resource-limited settings like Ethiopia. Similar resistance patterns have been documented in studies conducted among patients on second-line ART in various African countries, including Rwanda, Uganda, Namibia, Gabon, South Africa, and Zambia [<xref rid="B29-viruses-17-00206" ref-type="bibr">29</xref>,<xref rid="B41-viruses-17-00206" ref-type="bibr">41</xref>,<xref rid="B42-viruses-17-00206" ref-type="bibr">42</xref>,<xref rid="B43-viruses-17-00206" ref-type="bibr">43</xref>,<xref rid="B44-viruses-17-00206" ref-type="bibr">44</xref>]. These complex mutation patterns, characterized by high rates of M184V mutations and TAMs, are typically attributed to several common factors in these settings as follows: limited availability of resistance testing, prolonged periods of VF while on first-line therapy, the use of suboptimal treatment regimens, and challenges with medication adherence [<xref rid="B45-viruses-17-00206" ref-type="bibr">45</xref>,<xref rid="B46-viruses-17-00206" ref-type="bibr">46</xref>]. These circumstances collectively contribute to the development and accumulation of DRMs, potentially compromising the efficacy of second-line ART regimens and complicating long-term HIV management in these regions.</p><p>We detected NNRTI-associated DRMs in 65% of patients, even though NNRTIs are typically excluded from second-line ART regimens. This indicates persistence of NNRTI-resistant viral strains even after discontinuation of NNRTI-based therapies [<xref rid="B39-viruses-17-00206" ref-type="bibr">39</xref>]. Similar results from other studies have shown that NNRTI-associated DRMs often remain detectable in patients transitioning to second-line regimens following failure of first-line treatments [<xref rid="B43-viruses-17-00206" ref-type="bibr">43</xref>,<xref rid="B44-viruses-17-00206" ref-type="bibr">44</xref>,<xref rid="B45-viruses-17-00206" ref-type="bibr">45</xref>,<xref rid="B47-viruses-17-00206" ref-type="bibr">47</xref>]. The most frequently observed NNRTI-associated mutations include K103N, Y181C, and G190A. These mutations are known to confer high-level resistance to first-generation NNRTIs such as efavirenz and nevirapine, which are commonly used in first-line regimens [<xref rid="B46-viruses-17-00206" ref-type="bibr">46</xref>]. Furthermore, the additional mutations detected, such as H221Y, V106M, V108I, A98G, and L100I, can contribute to cross-resistance within the NNRTI class and may impact the effectiveness of newer NNRTIs like etravirine and rilpivirine [<xref rid="B48-viruses-17-00206" ref-type="bibr">48</xref>]. Our findings are consistent with findings from several studies conducted in resource-limited settings [<xref rid="B44-viruses-17-00206" ref-type="bibr">44</xref>,<xref rid="B49-viruses-17-00206" ref-type="bibr">49</xref>,<xref rid="B50-viruses-17-00206" ref-type="bibr">50</xref>,<xref rid="B51-viruses-17-00206" ref-type="bibr">51</xref>].</p><p>Our study&#x02019;s finding of an 18.92% prevalence of PI-associated DRMs among patients on second-line regimens is supported by previous research in similar settings [<xref rid="B44-viruses-17-00206" ref-type="bibr">44</xref>,<xref rid="B45-viruses-17-00206" ref-type="bibr">45</xref>]. A pooled analysis of PI-based treatment failures in sub-Saharan Africa reported that 17% of patients had at least one major PI-resistance mutation at the time of treatment failure [<xref rid="B43-viruses-17-00206" ref-type="bibr">43</xref>]. Studies from Namibia, Uganda, and South Africa reported 13.1%, 19.4%, and 22% of PI-associated HIVDRMs, respectively, among people receiving PI/r-based second-line ART [<xref rid="B29-viruses-17-00206" ref-type="bibr">29</xref>,<xref rid="B41-viruses-17-00206" ref-type="bibr">41</xref>,<xref rid="B44-viruses-17-00206" ref-type="bibr">44</xref>,<xref rid="B52-viruses-17-00206" ref-type="bibr">52</xref>]. However, our results are lower than those reported in other studies. For instance, Chimukangara et al. found in South Africa that among 348 samples analyzed, 287 (82.5%) had at least one DRM and 114 (32.8%) had at least one major PI-resistance DRM [<xref rid="B53-viruses-17-00206" ref-type="bibr">53</xref>]. Similarly, a systematic review conducted in Asia by Ross et al. revealed that 13 out of 39 patients (33%) had major PI DRMs [<xref rid="B54-viruses-17-00206" ref-type="bibr">54</xref>].</p><p>The V82A mutation, detected in 29.41% of patients, is a major PI resistance mutation that can significantly reduce susceptibility to several PIs, including lopinavir and indinavir. The I54IV/V and M46I mutations, each found in 23.53% of patients, are also major PI resistance mutations that can contribute to reduced PI efficacy. The presence of I50L, L90M, and N88S mutations, albeit at lower frequencies, further underscores the complexity of PI resistance patterns in this cohort. The I50L mutation is particularly associated with resistance to atazanavir, while L90M can confer broad cross-resistance to multiple PIs [<xref rid="B25-viruses-17-00206" ref-type="bibr">25</xref>,<xref rid="B36-viruses-17-00206" ref-type="bibr">36</xref>]. Several studies among patients receiving second-line PI-based regimens have documented similar PI-associated mutations [<xref rid="B42-viruses-17-00206" ref-type="bibr">42</xref>,<xref rid="B43-viruses-17-00206" ref-type="bibr">43</xref>,<xref rid="B44-viruses-17-00206" ref-type="bibr">44</xref>,<xref rid="B45-viruses-17-00206" ref-type="bibr">45</xref>].</p><p>The relatively low prevalence of PI mutations (18.92%) and the high level of susceptibility to DRV, ATV, and LPV among the majority of participants in our study suggest that PI-based regimens may still be an effective backbone of most second-line regimens for many patients failing second-line therapy, provided adherence issues are addressed. However, the presence of PI mutations in some patients underscores the need for careful monitoring and resistance testing to ensure these patients are prescribed effective third-line ART regimens.</p><p>Our result highlights a significant association between the duration of second-line ART and viral load suppression. Participants who had been on second-line ART for over 12 months had significantly lower odds of viral load failure compared to those treated for less than 12 months (AOR: 0.52, 95% CI: 1.52&#x02013;4.28). The improved outcomes associated with longer ART duration may be attributed to enhanced medication adherence over time [<xref rid="B55-viruses-17-00206" ref-type="bibr">55</xref>]. As patients become more accustomed to their treatment regimens and learn to manage side effects, adherence likely improves, resulting in better viral suppression. Additionally, extended periods of viral suppression reduce the risk of DRMs, which are more likely to arise when viral replication is poorly controlled. This is especially important in the context of second-line therapy, where treatment options become more limited, and maintaining the effectiveness of available drugs is crucial. Early identification of at-risk individuals through viral load monitoring and adherence support can improve long-term outcomes. Consistent with previous research, our findings suggest that providing intensive adherence support and regular VL monitoring during the early stages of second-line therapy is critical to enhance the likelihood of achieving and maintaining viral suppression and treatment success over time [<xref rid="B45-viruses-17-00206" ref-type="bibr">45</xref>,<xref rid="B53-viruses-17-00206" ref-type="bibr">53</xref>]. This is more significant in resource-limited settings where third-line ART options are limited.</p><p>Our study also reveals significant associations between occupation and VF among participants on second-line ART. Students emerged as the group with the highest risk (AOR: 6.14, 95% CI: 1.93&#x02013;19.48) compared to government employees. Students may face unique adherence difficulties, such as balancing academic responsibilities, social life, and health management [<xref rid="B56-viruses-17-00206" ref-type="bibr">56</xref>]. Furthermore, as young adults, they may experience greater stigma or lack of access to consistent healthcare, making adherence more challenging [<xref rid="B56-viruses-17-00206" ref-type="bibr">56</xref>]. Additionally, stress, depression, and anxiety are prevalent among students and can disrupt consistent ART adherence. Our findings underscore the importance of designing interventions tailored to students&#x02019; unique circumstances, including flexible healthcare delivery models (e.g., mobile health units and telemedicine), enhanced adherence support, and psychosocial counseling to address their specific challenges [<xref rid="B57-viruses-17-00206" ref-type="bibr">57</xref>].</p><p>Although not statistically significant, individuals in occupations such as drivers, unemployed persons, and those classified under &#x0201c;other&#x0201d; categories demonstrated increased odds of VF. For example, drivers often contend with irregular work schedules and extended periods away from home, which can disrupt medication adherence and hinder regular clinic attendance. To address these challenges, adherence interventions for drivers could involve strategies such as providing multi-month medication supplies or offering flexible clinic appointment times. These measures would help ensure that drivers can maintain their treatment regimens despite the demands and unpredictability of their work environments [<xref rid="B58-viruses-17-00206" ref-type="bibr">58</xref>]. Overall, these findings highlight the critical importance of ensuring comprehensive adherence support for all patients on second-line ART, regardless of their occupation.</p><p>Our results showed a relationship between CD4 count and the likelihood of viral load failure among individuals on second-line ART. Specifically, participants with a CD4 count below 200 cells/mm<sup>3</sup> were found to have 2.55 times higher odds (AOR: 2.55; 95% CI: 1.52&#x02013;4.28) of experiencing VF compared to those with CD4 counts at and above this threshold. This suggests that individuals with lower CD4 counts, indicative of more pronounced immunosuppression, are at heightened risk of treatment failure. Our findings align with other studies that similarly report an increased risk of VF associated with low baseline CD4 counts, which is often accompanied by HIVDR [<xref rid="B27-viruses-17-00206" ref-type="bibr">27</xref>,<xref rid="B28-viruses-17-00206" ref-type="bibr">28</xref>,<xref rid="B30-viruses-17-00206" ref-type="bibr">30</xref>,<xref rid="B59-viruses-17-00206" ref-type="bibr">59</xref>,<xref rid="B60-viruses-17-00206" ref-type="bibr">60</xref>].</p><p>The genetic diversity of HIV-1 in the study group aligns with the typical diversity observed in different studies in Ethiopia. It highlights the clear dominance of subtype C in the country, with 94.59% (35 out of 37) of the sequences clustering within this subtype [<xref rid="B17-viruses-17-00206" ref-type="bibr">17</xref>,<xref rid="B61-viruses-17-00206" ref-type="bibr">61</xref>,<xref rid="B62-viruses-17-00206" ref-type="bibr">62</xref>,<xref rid="B63-viruses-17-00206" ref-type="bibr">63</xref>].</p><sec><title>Limitation of This Study</title><p>This study marks a significant milestone as the first national survey to encompass multiple health facilities, yet it is not without its limitations. The relatively small sample size poses a challenge, potentially failing to accurately represent the broader population of patients on second-line therapy, which in turn restricts the generalizability of the findings. We defined VF as a single viral load measurement of &#x02265;1000 copies/mL, without the requirement for a second confirmatory test. This approach could potentially overestimate the incidence of VF. The overall genotyping success rate was 45.68%, which might have influenced the study results. Moreover, the cross-sectional nature of the study design only provides a snapshot of resistance mutations at a single point in time, preventing any assessment of longitudinal changes or the progression of these mutations over an extended period. To address these limitations and gain a more comprehensive understanding of the evolution of resistance mutations and their clinical implications among patients on second-line regimens, future research should focus on incorporating larger, more diverse cohorts and implementing longitudinal follow-up strategies.</p></sec></sec><sec sec-type="conclusions" id="sec5-viruses-17-00206"><title>5. Conclusions</title><p>This study, the first national HIVDR survey conducted in selected health facilities in Ethiopia, indicates that 13.82% of patients on second-line ART did not achieve viral suppression. This study identified both dual-class and triple-class resistance among those experiencing virological failure, indicating a substantial challenge in managing HIVDR. This underscores the need for comprehensive HIV care in Ethiopia, which should include adherence support, regular viral load monitoring, and HIVDR testing for patients on second-line ART. Notably, the relatively low prevalence of PIs mutations and the high level of susceptibility to PIs suggest that PI-based regimens could remain effective as the backbone of second-line regimens, provided that adherence issues are adequately addressed.</p></sec></body><back><ack><title>Acknowledgments</title><p>We extend our sincere gratitude to the study participants and all the staff who contributed to the survey. We also acknowledge the support provided by the WHO and the National Institute of Respiratory Diseases-Mexico (INER) laboratory for HIVDR genotyping.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, K.Z., A.G., P.M. and D.A.A.; methodology, K.Z., A.G. and D.A.A.; data curation, K.Z. and D.A.A.; formal analysis, D.A.A., K.Z. and P.M.; funding acquisition, K.Z., A.G. and D.A.A.; investigation, K.Z., D.A.A., A.G., S.S., Y.G., E.K., B.W., A.Y. (Ajanaw Yizengaw), G.G., S.A., M.Y., A.Y. (Amelework Yilma) and S.T.; project administration, K.Z., A.G. and D.A.A.; supervision, K.Z., A.G. and D.A.A.; visualization, K.Z. and D.A.A.; writing&#x02014;original draft, K.Z. and D.A.A.; writing&#x02014;review and editing, K.Z., S.S., P.M. and D.A.A. All authors revised the manuscript and provided important intellectual content. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki and approved by the Research and Ethical Clearance Committee of EPHI and the National Health Research Ethics Review Committee of the Ministry of Science and Technology of Ethiopia (SERO-60-2016; Version 001, on 11 May 2016).</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent was obtained from all participants for the national HIV drug-resistance survey.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All the sequences from this study will be deposited in GenBank.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00206"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>McMahon</surname><given-names>R.</given-names></name>
</person-group><source>UNAIDS Issues New Fast-Track Strategy to End AIDS by 2030</source><publisher-name>Elizabeth Glaser Pediatric AIDS Foundation</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2014</year></element-citation></ref><ref id="B2-viruses-17-00206"><label>2.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Policy Brief: Update of Recommendations on First- and Second-Line Antiretroviral Regimens</article-title><year>2019</year><comment>Available online: <ext-link xlink:href="https://apps.who.int/iris/handle/10665/325892" ext-link-type="uri">https://apps.who.int/iris/handle/10665/325892</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-09-20">(accessed on 20 September 2023)</date-in-citation></element-citation></ref><ref id="B3-viruses-17-00206"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gregson</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>M.</given-names></name>
<name><surname>Ndembi</surname><given-names>N.</given-names></name>
<name><surname>Hamers</surname><given-names>R.L.</given-names></name>
<name><surname>Rhee</surname><given-names>S.-Y.</given-names></name>
<name><surname>Marconi</surname><given-names>V.C.</given-names></name>
<name><surname>Diero</surname><given-names>L.</given-names></name>
<name><surname>Brooks</surname><given-names>K.A.</given-names></name>
<name><surname>Theys</surname><given-names>K.</given-names></name>
<name><surname>Rinke de Wit</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study</article-title><source>Lancet Infect. Dis.</source><year>2016</year><volume>16</volume><fpage>565</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00536-8</pub-id><pub-id pub-id-type="pmid">26831472</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00206"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Global Action Plan on HIV Drug Resistance 2017&#x02013;2021</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2017</year></element-citation></ref><ref id="B5-viruses-17-00206"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertagnolio</surname><given-names>S.</given-names></name>
<name><surname>Beanland</surname><given-names>R.L.</given-names></name>
<name><surname>Jordan</surname><given-names>M.R.</given-names></name>
<name><surname>Doherty</surname><given-names>M.</given-names></name>
<name><surname>Hirnschall</surname><given-names>G.</given-names></name>
</person-group><article-title>The World Health Organization&#x02019;s response to emerging human immunodeficiency virus drug resistance and a call for global action</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>216</volume><fpage>S801</fpage><lpage>S804</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix402</pub-id><pub-id pub-id-type="pmid">29040686</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00206"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bernab&#x000e9;</surname><given-names>K.J.</given-names></name>
<name><surname>Siedner</surname><given-names>M.</given-names></name>
<name><surname>Tsai</surname><given-names>A.C.</given-names></name>
<name><surname>Marconi</surname><given-names>V.C.</given-names></name>
<name><surname>Murphy</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Detection of HIV Virologic Failure and Switch to Second-Line Therapy: A Systematic Review and Meta-analysis of Data from Sub-Saharan Africa</article-title><source>Open Forum Infect. Dis.</source><year>2022</year><volume>9</volume><fpage>ofac121</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofac121</pub-id><pub-id pub-id-type="pmid">35434173</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00206"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Federal Ministry of Health of Ethiopia</collab>
</person-group><source>National Consolidated Guidelines for Comprehensive HIV Prevention, Care and Treatment</source><publisher-name>Fmoh</publisher-name><publisher-loc>Addis Ababa, Ethiopia</publisher-loc><year>2018</year><fpage>1</fpage><lpage>238</lpage></element-citation></ref><ref id="B8-viruses-17-00206"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Ethiopian Public Health Institute (EPHI)</collab>
</person-group><source>Ethiopia Population-based HIV Impact Assessment (EPHIA) 2017&#x02013;2018. Final Report</source><publisher-name>EPHI</publisher-name><publisher-loc>Addis Ababa, Ethiopia</publisher-loc><year>2020</year></element-citation></ref><ref id="B9-viruses-17-00206"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sawadogo</surname><given-names>S.</given-names></name>
<name><surname>Shiningavamwe</surname><given-names>A.N.</given-names></name>
<name><surname>Roscoe</surname><given-names>C.</given-names></name>
<name><surname>Baughman</surname><given-names>A.L.</given-names></name>
<name><surname>Negussie</surname><given-names>T.</given-names></name>
<name><surname>Mutandi</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Hamunime</surname><given-names>N.</given-names></name>
<name><surname>Agolory</surname><given-names>S.</given-names></name>
</person-group><article-title>Human Immunodeficiency Virus-1 Drug Resistance Patterns Among Adult Patients Failing Second-Line Protease Inhibitor-Containing Regimens in Namibia, 2010&#x02013;2015</article-title><source>Open Forum Infect. Dis.</source><year>2018</year><volume>5</volume><fpage>ofy014</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofy014</pub-id><pub-id pub-id-type="pmid">30568984</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00206"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Surveillance of HIV Drug Resistance in Populations Initiating Antiretroviral Therapy (Pre-Treatment HIV Drug Resistance): Concept Note</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2014</year></element-citation></ref><ref id="B11-viruses-17-00206"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>WHO HIVResNet HIV Drug Resistance Laboratory Operational Framework</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2020</year></element-citation></ref><ref id="B12-viruses-17-00206"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000c1;vila-R&#x000ed;os</surname><given-names>S.</given-names></name>
<name><surname>Garc&#x000ed;a-Morales</surname><given-names>C.</given-names></name>
<name><surname>Valenzuela-Lara</surname><given-names>M.</given-names></name>
<name><surname>Chaillon</surname><given-names>A.</given-names></name>
<name><surname>Tapia-Trejo</surname><given-names>D.</given-names></name>
<name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>M.</given-names></name>
<name><surname>L&#x000f3;pez-S&#x000e1;nchez</surname><given-names>D.M.</given-names></name>
<name><surname>Maza-S&#x000e1;nchez</surname><given-names>L.</given-names></name>
<name><surname>Del Arenal-S&#x000e1;nchez</surname><given-names>S.J.</given-names></name>
<name><surname>Paz-Ju&#x000e1;rez</surname><given-names>H.E.</given-names></name>
<etal/>
</person-group><article-title>HIV-1 drug resistance before initiation or re-initiation of first-line ART in eight regions of Mexico: A sub-nationally representative survey</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>1044</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1093/jac/dky512</pub-id><pub-id pub-id-type="pmid">30597094</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00206"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woods</surname><given-names>C.K.</given-names></name>
<name><surname>Brumme</surname><given-names>C.J.</given-names></name>
<name><surname>Liu</surname><given-names>T.F.</given-names></name>
<name><surname>Chui</surname><given-names>C.K.</given-names></name>
<name><surname>Chu</surname><given-names>A.L.</given-names></name>
<name><surname>Wynhoven</surname><given-names>B.</given-names></name>
<name><surname>Hall</surname><given-names>T.A.</given-names></name>
<name><surname>Trevino</surname><given-names>C.</given-names></name>
<name><surname>Shafer</surname><given-names>R.W.</given-names></name>
<name><surname>Harrigan</surname><given-names>P.R.</given-names></name>
</person-group><article-title>Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool</article-title><source>J. Clin. Microbiol.</source><year>2012</year><volume>50</volume><fpage>1936</fpage><lpage>1942</lpage><pub-id pub-id-type="doi">10.1128/JCM.06689-11</pub-id><pub-id pub-id-type="pmid">22403431</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00206"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pineda-Pe&#x000f1;a</surname><given-names>A.C.</given-names></name>
<name><surname>Faria</surname><given-names>N.R.</given-names></name>
<name><surname>Imbrechts</surname><given-names>S.</given-names></name>
<name><surname>Libin</surname><given-names>P.</given-names></name>
<name><surname>Abecasis</surname><given-names>A.B.</given-names></name>
<name><surname>Deforche</surname><given-names>K.</given-names></name>
<name><surname>G&#x000f3;mez-L&#x000f3;pez</surname><given-names>A.</given-names></name>
<name><surname>Camacho</surname><given-names>R.J.</given-names></name>
<name><surname>de Oliveira</surname><given-names>T.</given-names></name>
<name><surname>Vandamme</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools</article-title><source>Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis.</source><year>2013</year><volume>19</volume><fpage>337</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2013.04.032</pub-id></element-citation></ref><ref id="B15-viruses-17-00206"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Struck</surname><given-names>D.</given-names></name>
<name><surname>Lawyer</surname><given-names>G.</given-names></name>
<name><surname>Ternes</surname><given-names>A.M.</given-names></name>
<name><surname>Schmit</surname><given-names>J.C.</given-names></name>
<name><surname>Bercoff</surname><given-names>D.P.</given-names></name>
</person-group><article-title>COMET: Adaptive context-based modeling for ultrafast HIV-1 subtype identification</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>e144</fpage><pub-id pub-id-type="doi">10.1093/nar/gku739</pub-id><pub-id pub-id-type="pmid">25120265</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00206"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arimide</surname><given-names>D.A.</given-names></name>
<name><surname>Esquivel-G&#x000f3;mez</surname><given-names>L.R.</given-names></name>
<name><surname>Kebede</surname><given-names>Y.</given-names></name>
<name><surname>Sasinovich</surname><given-names>S.</given-names></name>
<name><surname>Balcha</surname><given-names>T.</given-names></name>
<name><surname>Bj&#x000f6;rkman</surname><given-names>P.</given-names></name>
<name><surname>K&#x000fc;hnert</surname><given-names>D.</given-names></name>
<name><surname>Medstrand</surname><given-names>P.</given-names></name>
</person-group><article-title>Molecular Epidemiology and Transmission Dynamics of the HIV-1 Epidemic in Ethiopia: Epidemic Decline Coincided with Behavioral Interventions Before ART Scale-Up</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>821006</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.821006</pub-id><pub-id pub-id-type="pmid">35283836</pub-id>
</element-citation></ref><ref id="B17-viruses-17-00206"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arimide</surname><given-names>D.A.</given-names></name>
<name><surname>Abebe</surname><given-names>A.</given-names></name>
<name><surname>Kebede</surname><given-names>Y.</given-names></name>
<name><surname>Adugna</surname><given-names>F.</given-names></name>
<name><surname>Tilahun</surname><given-names>T.</given-names></name>
<name><surname>Kassa</surname><given-names>D.</given-names></name>
<name><surname>Assefa</surname><given-names>Y.</given-names></name>
<name><surname>Balcha</surname><given-names>T.T.</given-names></name>
<name><surname>Bj&#x000f6;rkman</surname><given-names>P.</given-names></name>
<name><surname>Medstrand</surname><given-names>P.</given-names></name>
</person-group><article-title>HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003&#x02013;2013</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0205446</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0205446</pub-id><pub-id pub-id-type="pmid">30304061</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00206"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katoh</surname><given-names>K.</given-names></name>
<name><surname>Kuma</surname><given-names>K.-I.</given-names></name>
<name><surname>Miyata</surname><given-names>T.</given-names></name>
<name><surname>Toh</surname><given-names>H.</given-names></name>
</person-group><article-title>Improvement in the accuracy of multiple sequence alignment program MAFFT</article-title><source>Genome Inform.</source><year>2005</year><volume>16</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16362903</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00206"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Hall</surname><given-names>T.A.</given-names></name>
</person-group><article-title>BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT</article-title><source>Nucleic Acids Symposium Series</source><publisher-name>Academia</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>1999</year><fpage>95</fpage><lpage>98</lpage></element-citation></ref><ref id="B20-viruses-17-00206"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arimide</surname><given-names>D.A.</given-names></name>
<name><surname>Szojka</surname><given-names>Z.I.</given-names></name>
<name><surname>Zealiyas</surname><given-names>K.</given-names></name>
<name><surname>Gebreegziabxier</surname><given-names>A.</given-names></name>
<name><surname>Adugna</surname><given-names>F.</given-names></name>
<name><surname>Sasinovich</surname><given-names>S.</given-names></name>
<name><surname>Bj&#x000f6;rkman</surname><given-names>P.</given-names></name>
<name><surname>Medstrand</surname><given-names>P.</given-names></name>
</person-group><article-title>Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>729</elocation-id><pub-id pub-id-type="doi">10.3390/v14040729</pub-id><pub-id pub-id-type="pmid">35458459</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00206"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guindon</surname><given-names>S.</given-names></name>
<name><surname>Dufayard</surname><given-names>J.-F.</given-names></name>
<name><surname>Lefort</surname><given-names>V.</given-names></name>
<name><surname>Anisimova</surname><given-names>M.</given-names></name>
<name><surname>Hordijk</surname><given-names>W.</given-names></name>
<name><surname>Gascuel</surname><given-names>O.</given-names></name>
</person-group><article-title>New Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML 3.0</article-title><source>Syst. Biol.</source><year>2010</year><volume>59</volume><fpage>307</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1093/sysbio/syq010</pub-id><pub-id pub-id-type="pmid">20525638</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00206"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guindon</surname><given-names>S.</given-names></name>
<name><surname>Lethiec</surname><given-names>F.</given-names></name>
<name><surname>Duroux</surname><given-names>P.</given-names></name>
<name><surname>Gascuel</surname><given-names>O.</given-names></name>
</person-group><article-title>PHYML Online&#x02014;A web server for fast maximum likelihood-based phylogenetic inference</article-title><source>Nucleic Acids Res.</source><year>2005</year><volume>33</volume><fpage>W557</fpage><lpage>W559</lpage><pub-id pub-id-type="doi">10.1093/nar/gki352</pub-id><pub-id pub-id-type="pmid">15980534</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00206"><label>23.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Rambaut</surname><given-names>A.</given-names></name>
</person-group><article-title>FigTree 1.4. 3</article-title><year>2016</year><comment>Available online: <ext-link xlink:href="http://tree.bio.ed.ac.uk/software/figtree" ext-link-type="uri">http://tree.bio.ed.ac.uk/software/figtree</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-16">(accessed on 16 March 2023)</date-in-citation></element-citation></ref><ref id="B24-viruses-17-00206"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosseinipour</surname><given-names>M.C.</given-names></name>
<name><surname>Gupta</surname><given-names>R.K.</given-names></name>
<name><surname>Van Zyl</surname><given-names>G.</given-names></name>
<name><surname>Eron</surname><given-names>J.J.</given-names></name>
<name><surname>Nachega</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings</article-title><source>J. Infect. Dis.</source><year>2013</year><volume>207</volume><issue>(Suppl. 2)</issue><fpage>S49</fpage><lpage>S56</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit107</pub-id><pub-id pub-id-type="pmid">23687289</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00206"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ajose</surname><given-names>O.</given-names></name>
<name><surname>Mookerjee</surname><given-names>S.</given-names></name>
<name><surname>Mills</surname><given-names>E.J.</given-names></name>
<name><surname>Boulle</surname><given-names>A.</given-names></name>
<name><surname>Ford</surname><given-names>N.</given-names></name>
</person-group><article-title>Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: A systematic review and meta-analysis</article-title><source>Aids</source><year>2012</year><volume>26</volume><fpage>929</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328351f5b2</pub-id><pub-id pub-id-type="pmid">22313953</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00206"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>R.A.</given-names></name>
<name><surname>Sunpath</surname><given-names>H.</given-names></name>
<name><surname>Castilla</surname><given-names>C.</given-names></name>
<name><surname>Ebrahim</surname><given-names>S.</given-names></name>
<name><surname>Court</surname><given-names>R.</given-names></name>
<name><surname>Nguyen</surname><given-names>H.</given-names></name>
<name><surname>Kuritzkes</surname><given-names>D.</given-names></name>
<name><surname>Marconi</surname><given-names>V.C.</given-names></name>
<name><surname>Nachega</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Second-line antiretroviral therapy: Long-term outcomes in South Africa</article-title><source>J. Acquir Immune Defic. Syndr.</source><year>2012</year><volume>61</volume><fpage>158</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3182615ad1</pub-id><pub-id pub-id-type="pmid">22692090</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00206"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mwavika</surname><given-names>E.T.</given-names></name>
<name><surname>Kunambi</surname><given-names>P.P.</given-names></name>
<name><surname>Masasi</surname><given-names>S.J.</given-names></name>
<name><surname>Lema</surname><given-names>N.</given-names></name>
<name><surname>Kamori</surname><given-names>D.</given-names></name>
<name><surname>Matee</surname><given-names>M.</given-names></name>
</person-group><article-title>Prevalence, rate, and predictors of virologic failure among adult HIV-Infected clients on second-line antiretroviral therapy (ART) in Tanzania (2018&#x02013;2020): A retrospective cohort study</article-title><source>Bull. Natl. Res. Cent.</source><year>2024</year><volume>48</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/s42269-024-01248-5</pub-id></element-citation></ref><ref id="B28-viruses-17-00206"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gunda</surname><given-names>D.W.</given-names></name>
<name><surname>Kilonzo</surname><given-names>S.B.</given-names></name>
<name><surname>Mtaki</surname><given-names>T.</given-names></name>
<name><surname>Bernard</surname><given-names>D.M.</given-names></name>
<name><surname>Kalluvya</surname><given-names>S.E.</given-names></name>
<name><surname>Shao</surname><given-names>E.R.</given-names></name>
</person-group><article-title>Magnitude and correlates of virological failure among adult HIV patients receiving PI based second line ART regimens in north western Tanzania; A case control study</article-title><source>BMC Infect. Dis.</source><year>2019</year><volume>19</volume><elocation-id>235</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-019-3852-3</pub-id><pub-id pub-id-type="pmid">30845924</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00206"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ndahimana</surname><given-names>J.d.A.</given-names></name>
<name><surname>Riedel</surname><given-names>D.J.</given-names></name>
<name><surname>Muhayimpundu</surname><given-names>R.</given-names></name>
<name><surname>Nsanzimana</surname><given-names>S.</given-names></name>
<name><surname>Niyibizi</surname><given-names>G.</given-names></name>
<name><surname>Mutaganzwa</surname><given-names>E.</given-names></name>
<name><surname>Mulindabigwi</surname><given-names>A.</given-names></name>
<name><surname>Baribwira</surname><given-names>C.</given-names></name>
<name><surname>Kiromera</surname><given-names>A.</given-names></name>
<name><surname>Jagodzinski</surname><given-names>L.L.</given-names></name>
<etal/>
</person-group><article-title>HIV drug Resistance Mutations among Patients Failing Second-Line Antiretroviral Therapy in Rwanda</article-title><source>Antivir. Ther.</source><year>2016</year><volume>21</volume><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.3851/IMP3005</pub-id><pub-id pub-id-type="pmid">26562173</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00206"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zakaria</surname><given-names>H.F.</given-names></name>
<name><surname>Raru</surname><given-names>T.B.</given-names></name>
<name><surname>Hassen</surname><given-names>F.A.</given-names></name>
<name><surname>Ayana</surname><given-names>G.M.</given-names></name>
<name><surname>Merga</surname><given-names>B.T.</given-names></name>
<name><surname>Debele</surname><given-names>G.R.</given-names></name>
<name><surname>Kiflemariam</surname><given-names>G.</given-names></name>
<name><surname>Kebede</surname><given-names>S.A.</given-names></name>
<name><surname>Ayele</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Incidence and Predictors of Virological Failure Among Adult HIV/AIDS Patients on Second-Line Anti-Retroviral Therapy, in Selected Public Hospital of Addis Ababa, Ethiopia: Retrospective Follow-Up Study</article-title><source>HIV AIDS (Auckl.)</source><year>2022</year><volume>14</volume><fpage>319</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.2147/HIV.S367677</pub-id><pub-id pub-id-type="pmid">35836751</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00206"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levison</surname><given-names>J.H.</given-names></name>
<name><surname>Orrell</surname><given-names>C.</given-names></name>
<name><surname>Losina</surname><given-names>E.</given-names></name>
<name><surname>Lu</surname><given-names>Z.</given-names></name>
<name><surname>Freedberg</surname><given-names>K.A.</given-names></name>
<name><surname>Wood</surname><given-names>R.</given-names></name>
</person-group><article-title>Early Outcomes and the Virological Effect of Delayed Treatment Switching to Second-Line Therapy in An Antiretroviral Roll-Out Programme in South Africa</article-title><source>Antivir. Ther.</source><year>2011</year><volume>16</volume><fpage>853</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.3851/IMP1819</pub-id><pub-id pub-id-type="pmid">21900717</pub-id>
</element-citation></ref><ref id="B32-viruses-17-00206"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levison</surname><given-names>J.H.</given-names></name>
<name><surname>Orrell</surname><given-names>C.</given-names></name>
<name><surname>Gallien</surname><given-names>S.</given-names></name>
<name><surname>Kuritzkes</surname><given-names>D.R.</given-names></name>
<name><surname>Fu</surname><given-names>N.</given-names></name>
<name><surname>Losina</surname><given-names>E.</given-names></name>
<name><surname>Freedberg</surname><given-names>K.A.</given-names></name>
<name><surname>Wood</surname><given-names>R.</given-names></name>
</person-group><article-title>Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e32144</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0032144</pub-id><pub-id pub-id-type="pmid">22427821</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00206"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moore</surname><given-names>D.M.</given-names></name>
<name><surname>Nanfuka</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Okoboi</surname><given-names>S.</given-names></name>
<name><surname>Kaleebu</surname><given-names>P.</given-names></name>
<name><surname>Kapaata</surname><given-names>A.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Tibengana</surname><given-names>B.</given-names></name>
<name><surname>Birungi</surname><given-names>J.</given-names></name>
</person-group><article-title>Limited Impact of First-Line Drug Resistance Mutations on Virologic Response Among Patients Receiving Second-Line Antiretroviral Therapy in Rural Uganda</article-title><source>JAIDS J. Acquir. Immune Defic. Syndr.</source><year>2023</year><volume>92</volume><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000003103</pub-id><pub-id pub-id-type="pmid">36150042</pub-id>
</element-citation></ref><ref id="B34-viruses-17-00206"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boender</surname><given-names>T.S.</given-names></name>
<name><surname>Hamers</surname><given-names>R.L.</given-names></name>
<name><surname>Ondoa</surname><given-names>P.</given-names></name>
<name><surname>Wellington</surname><given-names>M.</given-names></name>
<name><surname>Chimbetete</surname><given-names>C.</given-names></name>
<name><surname>Siwale</surname><given-names>M.</given-names></name>
<name><surname>Labib Maksimos</surname><given-names>E.E.F.</given-names></name>
<name><surname>Balinda</surname><given-names>S.N.</given-names></name>
<name><surname>Kityo</surname><given-names>C.M.</given-names></name>
<name><surname>Adeyemo</surname><given-names>T.A.</given-names></name>
<etal/>
</person-group><article-title>Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>214</volume><fpage>873</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw219</pub-id><pub-id pub-id-type="pmid">27402780</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00206"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Musana</surname><given-names>H.</given-names></name>
<name><surname>Ssensamba</surname><given-names>J.T.</given-names></name>
<name><surname>Nakafeero</surname><given-names>M.</given-names></name>
<name><surname>Mugerwa</surname><given-names>H.</given-names></name>
<name><surname>Kiweewa</surname><given-names>F.M.</given-names></name>
<name><surname>Serwadda</surname><given-names>D.</given-names></name>
<name><surname>Ssali</surname><given-names>F.</given-names></name>
</person-group><article-title>Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda</article-title><source>AIDS Res. Ther.</source><year>2021</year><volume>18</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s12981-021-00338-y</pub-id><pub-id pub-id-type="pmid">33882938</pub-id>
</element-citation></ref><ref id="B36-viruses-17-00206"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saravanan</surname><given-names>S.</given-names></name>
<name><surname>Vidya</surname><given-names>M.</given-names></name>
<name><surname>Balakrishnan</surname><given-names>P.</given-names></name>
<name><surname>Kantor</surname><given-names>R.</given-names></name>
<name><surname>Solomon</surname><given-names>S.S.</given-names></name>
<name><surname>Katzenstein</surname><given-names>D.</given-names></name>
<name><surname>Kumarasamy</surname><given-names>N.</given-names></name>
<name><surname>Yeptomi</surname><given-names>T.</given-names></name>
<name><surname>Sivamalar</surname><given-names>S.</given-names></name>
<name><surname>Rifkin</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Viremia and HIV-1 Drug Resistance Mutations Among Patients Receiving Second-Line Highly Active Antiretroviral Therapy in Chennai, Southern India</article-title><source>Clin. Infect. Dis.</source><year>2012</year><volume>54</volume><fpage>995</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1093/cid/cir967</pub-id><pub-id pub-id-type="pmid">22323567</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00206"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Zyl</surname><given-names>G.U.</given-names></name>
<name><surname>Liu</surname><given-names>T.F.</given-names></name>
<name><surname>Claassen</surname><given-names>M.</given-names></name>
<name><surname>Engelbrecht</surname><given-names>S.</given-names></name>
<name><surname>de Oliveira</surname><given-names>T.</given-names></name>
<name><surname>Preiser</surname><given-names>W.</given-names></name>
<name><surname>Wood</surname><given-names>N.T.</given-names></name>
<name><surname>Travers</surname><given-names>S.</given-names></name>
<name><surname>Shafer</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e67188</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0067188</pub-id><pub-id pub-id-type="pmid">23840622</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00206"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wallis</surname><given-names>C.L.</given-names></name>
<name><surname>Mellors</surname><given-names>J.W.</given-names></name>
<name><surname>Venter</surname><given-names>W.D.</given-names></name>
<name><surname>Sanne</surname><given-names>I.</given-names></name>
<name><surname>Stevens</surname><given-names>W.</given-names></name>
</person-group><article-title>Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa</article-title><source>AIDS Res. Treat</source><year>2011</year><volume>2011</volume><fpage>769627</fpage><pub-id pub-id-type="doi">10.1155/2011/769627</pub-id><pub-id pub-id-type="pmid">21490784</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00206"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sivamalar</surname><given-names>S.</given-names></name>
<name><surname>Dinesha</surname><given-names>T.R.</given-names></name>
<name><surname>Gomathi</surname><given-names>S.</given-names></name>
<name><surname>Pradeep</surname><given-names>A.</given-names></name>
<name><surname>Boobalan</surname><given-names>J.</given-names></name>
<name><surname>Solomon</surname><given-names>S.S.</given-names></name>
<name><surname>Poongulali</surname><given-names>S.</given-names></name>
<name><surname>Solomon</surname><given-names>S.</given-names></name>
<name><surname>Balakrishnan</surname><given-names>P.</given-names></name>
<name><surname>Saravanan</surname><given-names>S.</given-names></name>
</person-group><article-title>Accumulation of HIV-1 Drug Resistance Mutations After First-Line Immunological Failure to Evaluate the Options of Recycling NRTI Drugs in Second-Line Treatment: A Study from South India</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2016</year><volume>33</volume><fpage>271</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1089/aid.2016.0070</pub-id><pub-id pub-id-type="pmid">27460519</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00206"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arimide</surname><given-names>D.A.</given-names></name>
<name><surname>Amogne</surname><given-names>M.D.</given-names></name>
<name><surname>Kebede</surname><given-names>Y.</given-names></name>
<name><surname>Balcha</surname><given-names>T.T.</given-names></name>
<name><surname>Adugna</surname><given-names>F.</given-names></name>
<name><surname>Ramos</surname><given-names>A.</given-names></name>
<name><surname>DeVos</surname><given-names>J.</given-names></name>
<name><surname>Zeh</surname><given-names>C.</given-names></name>
<name><surname>Agardh</surname><given-names>A.</given-names></name>
<name><surname>Chih-Wei Chang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>High level of HIV drug resistance and virological non-suppression among female sex workers in Ethiopia: A nation-wide cross-sectional study</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2021</year><volume>89</volume><fpage>566</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000002908</pub-id><pub-id pub-id-type="pmid">34966147</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00206"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Namakoola</surname><given-names>I.</given-names></name>
<name><surname>Kasamba</surname><given-names>I.</given-names></name>
<name><surname>Mayanja</surname><given-names>B.N.</given-names></name>
<name><surname>Kazooba</surname><given-names>P.</given-names></name>
<name><surname>Lutaakome</surname><given-names>J.</given-names></name>
<name><surname>Lyagoba</surname><given-names>F.</given-names></name>
<name><surname>Kapaata</surname><given-names>A.A.</given-names></name>
<name><surname>Kaleebu</surname><given-names>P.</given-names></name>
<name><surname>Munderi</surname><given-names>P.</given-names></name>
<name><surname>On behalf of the Co</surname><given-names>L.s.t.</given-names></name>
</person-group><article-title>From antiretroviral therapy access to provision of third line regimens: Evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults</article-title><source>BMC Res. Notes</source><year>2016</year><volume>9</volume><elocation-id>515</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-016-2309-7</pub-id><pub-id pub-id-type="pmid">28010730</pub-id>
</element-citation></ref><ref id="B42-viruses-17-00206"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jordan</surname><given-names>M.R.</given-names></name>
<name><surname>Hamunime</surname><given-names>N.</given-names></name>
<name><surname>Bikinesi</surname><given-names>L.</given-names></name>
<name><surname>Sawadogo</surname><given-names>S.</given-names></name>
<name><surname>Agolory</surname><given-names>S.</given-names></name>
<name><surname>Shiningavamwe</surname><given-names>A.N.</given-names></name>
<name><surname>Negussie</surname><given-names>T.</given-names></name>
<name><surname>Fisher-Walker</surname><given-names>C.L.</given-names></name>
<name><surname>Raizes</surname><given-names>E.G.</given-names></name>
<name><surname>Mutenda</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia</article-title><source>Medicine</source><year>2020</year><volume>99</volume><fpage>e21661</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000021661</pub-id><pub-id pub-id-type="pmid">32925712</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00206"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nzengui-Nzengui</surname><given-names>G.F.</given-names></name>
<name><surname>Mourembou</surname><given-names>G.</given-names></name>
<name><surname>M&#x02019;boyis-Kamdem</surname><given-names>H.</given-names></name>
<name><surname>Kombila-Koumavor</surname><given-names>A.C.</given-names></name>
<name><surname>Ndjoyi-Mbiguino</surname><given-names>A.</given-names></name>
</person-group><article-title>HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon</article-title><source>BMC Infect. Dis.</source><year>2024</year><volume>24</volume><elocation-id>316</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-024-09156-9</pub-id><pub-id pub-id-type="pmid">38486188</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00206"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Obasa</surname><given-names>A.E.</given-names></name>
<name><surname>Mikasi</surname><given-names>S.G.</given-names></name>
<name><surname>Brado</surname><given-names>D.</given-names></name>
<name><surname>Cloete</surname><given-names>R.</given-names></name>
<name><surname>Singh</surname><given-names>K.</given-names></name>
<name><surname>Neogi</surname><given-names>U.</given-names></name>
<name><surname>Jacobs</surname><given-names>G.B.</given-names></name>
</person-group><article-title>Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>438</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.00438</pub-id><pub-id pub-id-type="pmid">32265875</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00206"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makwaga</surname><given-names>O.</given-names></name>
<name><surname>Adhiambo</surname><given-names>M.</given-names></name>
<name><surname>Mulama</surname><given-names>D.H.</given-names></name>
<name><surname>Muoma</surname><given-names>J.</given-names></name>
<name><surname>Adungo</surname><given-names>F.</given-names></name>
<name><surname>Wanjiku</surname><given-names>H.</given-names></name>
<name><surname>Ongaya</surname><given-names>A.</given-names></name>
<name><surname>Maitha</surname><given-names>G.M.</given-names></name>
<name><surname>Mwau</surname><given-names>M.</given-names></name>
</person-group><article-title>Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya</article-title><source>Pan Afr. Med. J.</source><year>2020</year><volume>37</volume><fpage>311</fpage><pub-id pub-id-type="doi">10.11604/pamj.2020.37.311.25909</pub-id><pub-id pub-id-type="pmid">33654530</pub-id>
</element-citation></ref><ref id="B46-viruses-17-00206"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamers</surname><given-names>R.L.</given-names></name>
<name><surname>Sigaloff</surname><given-names>K.C.E.</given-names></name>
<name><surname>Wensing</surname><given-names>A.M.</given-names></name>
<name><surname>Wallis</surname><given-names>C.L.</given-names></name>
<name><surname>Kityo</surname><given-names>C.</given-names></name>
<name><surname>Siwale</surname><given-names>M.</given-names></name>
<name><surname>Mandaliya</surname><given-names>K.</given-names></name>
<name><surname>Ive</surname><given-names>P.</given-names></name>
<name><surname>Botes</surname><given-names>M.E.</given-names></name>
<name><surname>Wellington</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies</article-title><source>Clin. Infect. Dis.</source><year>2012</year><volume>54</volume><fpage>1660</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1093/cid/cis254</pub-id><pub-id pub-id-type="pmid">22474222</pub-id>
</element-citation></ref><ref id="B47-viruses-17-00206"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Yue</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>He</surname><given-names>C.</given-names></name>
<name><surname>Liao</surname><given-names>L.</given-names></name>
<name><surname>Xing</surname><given-names>H.</given-names></name>
<name><surname>Ruan</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><elocation-id>14823</elocation-id><pub-id pub-id-type="doi">10.1038/srep14823</pub-id><pub-id pub-id-type="pmid">26445885</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00206"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melikian</surname><given-names>G.L.</given-names></name>
<name><surname>Rhee</surname><given-names>S.-Y.</given-names></name>
<name><surname>Varghese</surname><given-names>V.</given-names></name>
<name><surname>Porter</surname><given-names>D.P.</given-names></name>
<name><surname>White</surname><given-names>K.L.</given-names></name>
<name><surname>Taylor</surname><given-names>J.</given-names></name>
<name><surname>Towner</surname><given-names>W.J.</given-names></name>
<name><surname>Troia</surname><given-names>P.D.</given-names></name>
<name><surname>Burack</surname><given-names>J.H.</given-names></name>
<name><surname>Dejesus</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: Implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing</article-title><source>J. Antimicrob. Chemother.</source><year>2014</year><volume>69</volume><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1093/jac/dkt316</pub-id><pub-id pub-id-type="pmid">23934770</pub-id>
</element-citation></ref><ref id="B49-viruses-17-00206"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ismael</surname><given-names>N.</given-names></name>
<name><surname>Gemusse</surname><given-names>H.</given-names></name>
<name><surname>Mahumane</surname><given-names>I.</given-names></name>
<name><surname>Laurindo</surname><given-names>O.</given-names></name>
<name><surname>Magul</surname><given-names>C.</given-names></name>
<name><surname>Baxter</surname><given-names>C.</given-names></name>
<name><surname>Wilkinson</surname><given-names>E.</given-names></name>
<name><surname>Hofstra</surname><given-names>L.M.</given-names></name>
<name><surname>Wagar</surname><given-names>N.</given-names></name>
<name><surname>Bila</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ lamivudine /dolutegravir (TLD) roll-out in Mozambique</article-title><source>BMC Infect. Dis.</source><year>2024</year><volume>24</volume><elocation-id>748</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-024-09579-4</pub-id><pub-id pub-id-type="pmid">39075381</pub-id>
</element-citation></ref><ref id="B50-viruses-17-00206"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Derache</surname><given-names>A.</given-names></name>
<name><surname>Wallis</surname><given-names>C.L.</given-names></name>
<name><surname>Vardhanabhuti</surname><given-names>S.</given-names></name>
<name><surname>Bartlett</surname><given-names>J.</given-names></name>
<name><surname>Kumarasamy</surname><given-names>N.</given-names></name>
<name><surname>Katzenstein</surname><given-names>D.</given-names></name>
</person-group><article-title>Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>213</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv383</pub-id><pub-id pub-id-type="pmid">26175454</pub-id>
</element-citation></ref><ref id="B51-viruses-17-00206"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chimukangara</surname><given-names>B.</given-names></name>
<name><surname>Lessells</surname><given-names>R.J.</given-names></name>
<name><surname>Sartorius</surname><given-names>B.</given-names></name>
<name><surname>Gounder</surname><given-names>L.</given-names></name>
<name><surname>Manyana</surname><given-names>S.</given-names></name>
<name><surname>Pillay</surname><given-names>M.</given-names></name>
<name><surname>Singh</surname><given-names>L.</given-names></name>
<name><surname>Giandhari</surname><given-names>J.</given-names></name>
<name><surname>Govender</surname><given-names>K.</given-names></name>
<name><surname>Samuel</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2022</year><volume>29</volume><fpage>468</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2021.10.023</pub-id><pub-id pub-id-type="pmid">34785393</pub-id>
</element-citation></ref><ref id="B52-viruses-17-00206"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Obasa</surname><given-names>A.E.</given-names></name>
<name><surname>Ambikan</surname><given-names>A.T.</given-names></name>
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Neogi</surname><given-names>U.</given-names></name>
<name><surname>Jacobs</surname><given-names>G.B.</given-names></name>
</person-group><article-title>Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa</article-title><source>BMC Infect. Dis.</source><year>2021</year><volume>21</volume><elocation-id>214</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-021-05905-2</pub-id><pub-id pub-id-type="pmid">33632139</pub-id>
</element-citation></ref><ref id="B53-viruses-17-00206"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fox</surname><given-names>M.P.</given-names></name>
<name><surname>Berhanu</surname><given-names>R.</given-names></name>
<name><surname>Steegen</surname><given-names>K.</given-names></name>
<name><surname>Firnhaber</surname><given-names>C.</given-names></name>
<name><surname>Ive</surname><given-names>P.</given-names></name>
<name><surname>Spencer</surname><given-names>D.</given-names></name>
<name><surname>Mashamaite</surname><given-names>S.</given-names></name>
<name><surname>Sheik</surname><given-names>S.</given-names></name>
<name><surname>Jonker</surname><given-names>I.</given-names></name>
<name><surname>Howell</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa</article-title><source>Trop. Med. Int. Health</source><year>2016</year><volume>21</volume><fpage>1131</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1111/tmi.12741</pub-id><pub-id pub-id-type="pmid">27383454</pub-id>
</element-citation></ref><ref id="B54-viruses-17-00206"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ross</surname><given-names>J.</given-names></name>
<name><surname>Jiamsakul</surname><given-names>A.</given-names></name>
<name><surname>Kumarasamy</surname><given-names>N.</given-names></name>
<name><surname>Azwa</surname><given-names>I.</given-names></name>
<name><surname>Merati</surname><given-names>T.P.</given-names></name>
<name><surname>Do</surname><given-names>C.D.</given-names></name>
<name><surname>Lee</surname><given-names>M.P.</given-names></name>
<name><surname>Ly</surname><given-names>P.S.</given-names></name>
<name><surname>Yunihastuti</surname><given-names>E.</given-names></name>
<name><surname>Nguyen</surname><given-names>K.V.</given-names></name>
<etal/>
</person-group><article-title>Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific</article-title><source>HIV Med.</source><year>2021</year><volume>22</volume><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1111/hiv.13006</pub-id><pub-id pub-id-type="pmid">33151020</pub-id>
</element-citation></ref><ref id="B55-viruses-17-00206"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Shang</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Shang</surname><given-names>H.</given-names></name>
</person-group><article-title>Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China</article-title><source>BMC Infect. Dis.</source><year>2018</year><volume>18</volume><elocation-id>571</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-018-3489-7</pub-id><pub-id pub-id-type="pmid">30442114</pub-id>
</element-citation></ref><ref id="B56-viruses-17-00206"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Audi</surname><given-names>C.</given-names></name>
<name><surname>Jahanpour</surname><given-names>O.</given-names></name>
<name><surname>Antelman</surname><given-names>G.</given-names></name>
<name><surname>Guay</surname><given-names>L.</given-names></name>
<name><surname>Rutaihwa</surname><given-names>M.</given-names></name>
<name><surname>van de Ven</surname><given-names>R.</given-names></name>
<name><surname>Woelk</surname><given-names>G.</given-names></name>
<name><surname>Baird</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Facilitators and barriers to antiretroviral therapy adherence among HIV-positive adolescents living in Tanzania</article-title><source>BMC Public Health</source><year>2021</year><volume>21</volume><elocation-id>2274</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-021-12323-1</pub-id><pub-id pub-id-type="pmid">34903209</pub-id>
</element-citation></ref><ref id="B57-viruses-17-00206"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zurbachew</surname><given-names>Y.</given-names></name>
<name><surname>Hiko</surname><given-names>D.</given-names></name>
<name><surname>Bacha</surname><given-names>G.</given-names></name>
<name><surname>Merga</surname><given-names>H.</given-names></name>
</person-group><article-title>Adolescent&#x02019;s and youth&#x02019;s adherence to antiretroviral therapy for better treatment outcome and its determinants: Multi-center study in public health facilities</article-title><source>AIDS Res. Ther.</source><year>2023</year><volume>20</volume><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s12981-023-00588-y</pub-id><pub-id pub-id-type="pmid">38115098</pub-id>
</element-citation></ref><ref id="B58-viruses-17-00206"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moosa</surname><given-names>A.</given-names></name>
<name><surname>Gengiah</surname><given-names>T.N.</given-names></name>
<name><surname>Lewis</surname><given-names>L.</given-names></name>
<name><surname>Naidoo</surname><given-names>K.</given-names></name>
</person-group><article-title>Long-term adherence to antiretroviral therapy in a South African adult patient cohort: A retrospective study</article-title><source>BMC Infect. Dis.</source><year>2019</year><volume>19</volume><elocation-id>775</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-019-4410-8</pub-id><pub-id pub-id-type="pmid">31488063</pub-id>
</element-citation></ref><ref id="B59-viruses-17-00206"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gumede</surname><given-names>S.B.</given-names></name>
<name><surname>Venter</surname><given-names>F.</given-names></name>
<name><surname>de Wit</surname><given-names>J.</given-names></name>
<name><surname>Wensing</surname><given-names>A.</given-names></name>
<name><surname>Lalla-Edward</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Antiretroviral therapy uptake and predictors of virological failure in patients with HIV receiving first-line and second-line regimens in Johannesburg, South Africa: A retrospective cohort data analysis</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><fpage>e054019</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2021-054019</pub-id></element-citation></ref><ref id="B60-viruses-17-00206"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gidey</surname><given-names>K.</given-names></name>
<name><surname>Mache</surname><given-names>A.</given-names></name>
<name><surname>Hailu</surname><given-names>B.Y.</given-names></name>
<name><surname>Asgedom</surname><given-names>S.W.</given-names></name>
<name><surname>Tassew</surname><given-names>S.G.</given-names></name>
<name><surname>Nirayo</surname><given-names>Y.L.</given-names></name>
</person-group><article-title>Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia</article-title><source>Infect. Drug Resist</source><year>2023</year><volume>16</volume><fpage>4903</fpage><lpage>4912</lpage><pub-id pub-id-type="doi">10.2147/IDR.S419348</pub-id><pub-id pub-id-type="pmid">37534062</pub-id>
</element-citation></ref><ref id="B61-viruses-17-00206"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amogne</surname><given-names>W.</given-names></name>
<name><surname>Bontell</surname><given-names>I.</given-names></name>
<name><surname>Grossmann</surname><given-names>S.</given-names></name>
<name><surname>Aderaye</surname><given-names>G.</given-names></name>
<name><surname>Lindquist</surname><given-names>L.</given-names></name>
<name><surname>S&#x000f6;nnerborg</surname><given-names>A.</given-names></name>
<name><surname>Neogi</surname><given-names>U.</given-names></name>
</person-group><article-title>Phylogenetic analysis of Ethiopian HIV-1 subtype C near full-length genomes reveals high intrasubtype diversity and a strong geographical cluster</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2016</year><volume>32</volume><fpage>471</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1089/aid.2015.0380</pub-id><pub-id pub-id-type="pmid">26881451</pub-id>
</element-citation></ref><ref id="B62-viruses-17-00206"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abebe</surname><given-names>A.</given-names></name>
<name><surname>Pollakis</surname><given-names>G.</given-names></name>
<name><surname>Fontanet</surname><given-names>A.L.</given-names></name>
<name><surname>Fisseha</surname><given-names>B.</given-names></name>
<name><surname>Tegbaru</surname><given-names>B.</given-names></name>
<name><surname>Kliphuis</surname><given-names>A.</given-names></name>
<name><surname>Tesfaye</surname><given-names>G.</given-names></name>
<name><surname>Negassa</surname><given-names>H.</given-names></name>
<name><surname>Cornelissen</surname><given-names>M.</given-names></name>
<name><surname>Goudsmit</surname><given-names>J.</given-names></name>
</person-group><article-title>Identification of a genetic subcluster of HIV type 1 subtype C (C&#x02032;) widespread in Ethiopia</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2000</year><volume>16</volume><fpage>1909</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.1089/08892220050195865</pub-id><pub-id pub-id-type="pmid">11118076</pub-id>
</element-citation></ref><ref id="B63-viruses-17-00206"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pollakis</surname><given-names>G.</given-names></name>
<name><surname>Abebe</surname><given-names>A.</given-names></name>
<name><surname>Kliphuis</surname><given-names>A.</given-names></name>
<name><surname>De Wit</surname><given-names>T.F.R.</given-names></name>
<name><surname>Fisseha</surname><given-names>B.</given-names></name>
<name><surname>Tegbaru</surname><given-names>B.</given-names></name>
<name><surname>Tesfaye</surname><given-names>G.</given-names></name>
<name><surname>Negassa</surname><given-names>H.</given-names></name>
<name><surname>Mengistu</surname><given-names>Y.</given-names></name>
<name><surname>Fontanet</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Recombination of HIV type 1C (C&#x02032;/C&#x02033;) in Ethiopia: Possible link of EthHIV-1C&#x02032; to subtype C sequences from the high-prevalence epidemics in India and Southern Africa</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2003</year><volume>19</volume><fpage>999</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1089/088922203322588350</pub-id><pub-id pub-id-type="pmid">14678607</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00206-f001"><label>Figure 1</label><caption><p>The proportion of patients with HIV drug resistance mutation.</p></caption><graphic xlink:href="viruses-17-00206-g001" position="float"/></fig><fig position="float" id="viruses-17-00206-f002"><label>Figure 2</label><caption><p>The maximum-likelihood phylogenetics tree of HIV-1 subtypes and circulating recombinant forms circulating in Ethiopia. Subtype C reference sequences are depicted in blue, while non-subtype C Ethiopian sequences are shown in pink.</p></caption><graphic xlink:href="viruses-17-00206-g002" position="float"/></fig><table-wrap position="float" id="viruses-17-00206-t001"><object-id pub-id-type="pii">viruses-17-00206-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic characteristics of patients on second-line treatment in Ethiopia (<italic toggle="yes">n</italic> = 586).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic> (<italic toggle="yes">n</italic> = )
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Percent (%) </th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (Year)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;18&#x02013;24</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">5.97</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;25&#x02013;34</td><td align="center" valign="middle" rowspan="1" colspan="1">160</td><td align="center" valign="middle" rowspan="1" colspan="1">27.30</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;35&#x02013;44</td><td align="center" valign="middle" rowspan="1" colspan="1">245</td><td align="center" valign="middle" rowspan="1" colspan="1">41.81</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02265;45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">146</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.91</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Male </td><td align="center" valign="middle" rowspan="1" colspan="1">267</td><td align="center" valign="middle" rowspan="1" colspan="1">45.56</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Female </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">319</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.44</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Residence </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Urban </td><td align="center" valign="middle" rowspan="1" colspan="1">495</td><td align="center" valign="middle" rowspan="1" colspan="1">84.47</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Rural </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.53</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Marital status </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Unmarried </td><td align="center" valign="middle" rowspan="1" colspan="1">128</td><td align="center" valign="middle" rowspan="1" colspan="1">21.84</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Married, monogamous </td><td align="center" valign="middle" rowspan="1" colspan="1">234</td><td align="center" valign="middle" rowspan="1" colspan="1">39.93</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Married, polygamous </td><td align="center" valign="middle" rowspan="1" colspan="1">53</td><td align="center" valign="middle" rowspan="1" colspan="1">9.04</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Divorced</td><td align="center" valign="middle" rowspan="1" colspan="1">116</td><td align="center" valign="middle" rowspan="1" colspan="1">19.80</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Widowed </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.39</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Educational level </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;No formal education </td><td align="center" valign="middle" rowspan="1" colspan="1">117</td><td align="center" valign="middle" rowspan="1" colspan="1">19.97</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Primary education </td><td align="center" valign="middle" rowspan="1" colspan="1">259</td><td align="center" valign="middle" rowspan="1" colspan="1">44.20</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Secondary education </td><td align="center" valign="middle" rowspan="1" colspan="1">136</td><td align="center" valign="middle" rowspan="1" colspan="1">23.21</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;College or university </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.63</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Occupational status</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Government employee </td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">17.06</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Merchant </td><td align="center" valign="middle" rowspan="1" colspan="1">96</td><td align="center" valign="middle" rowspan="1" colspan="1">16.38</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Driver </td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">4.10</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Housewife</td><td align="center" valign="middle" rowspan="1" colspan="1">106</td><td align="center" valign="middle" rowspan="1" colspan="1">18.09</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Student</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">4.27</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Unemployed </td><td align="center" valign="middle" rowspan="1" colspan="1">90</td><td align="center" valign="middle" rowspan="1" colspan="1">15.36</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Other </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.74</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00206-t002"><object-id pub-id-type="pii">viruses-17-00206-t002_Table 2</object-id><label>Table 2</label><caption><p>Clinical characteristics and laboratory parameters of participants with HIV on second-line treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic> (<italic toggle="yes">n</italic> = )</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Percent (%)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Second-line ARV regimens</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 586</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;ABC + 3TC + ATV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">114</td><td align="center" valign="middle" rowspan="1" colspan="1">19.45</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;ABC + 3TC + LPV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">3.41</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;AZT + 3TC + ATV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">103</td><td align="center" valign="middle" rowspan="1" colspan="1">17.58</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;AZT + 3TC + LPV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">5.63</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;TDF + 3TC + ATV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">259</td><td align="center" valign="middle" rowspan="1" colspan="1">44.20</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;TDF + 3TC + LPV/r</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.73</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Duration on second-line regimen (months)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 586</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;6&#x02013;15</td><td align="center" valign="middle" rowspan="1" colspan="1">174</td><td align="center" valign="middle" rowspan="1" colspan="1">29.69</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;16&#x02013;48</td><td align="center" valign="middle" rowspan="1" colspan="1">327</td><td align="center" valign="middle" rowspan="1" colspan="1">55.80</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02265;49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.51</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">First-line ARV regimens</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 586</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;ABC + 3TC + EFV</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;ABC + 3TC + NVP</td><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">6.14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;AZT + 3TC + EFV</td><td align="center" valign="middle" rowspan="1" colspan="1">73</td><td align="center" valign="middle" rowspan="1" colspan="1">12.46</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;AZT + 3TC + NVP</td><td align="center" valign="middle" rowspan="1" colspan="1">157</td><td align="center" valign="middle" rowspan="1" colspan="1">26.79</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;D4T + 3TC + EFV</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">5.12</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;D4T + 3TC + NVP</td><td align="center" valign="middle" rowspan="1" colspan="1">89</td><td align="center" valign="middle" rowspan="1" colspan="1">15.19</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;TDF + 3TC + EFV</td><td align="center" valign="middle" rowspan="1" colspan="1">106</td><td align="center" valign="middle" rowspan="1" colspan="1">18.09</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;TDF + 3TC + NVP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.33</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Duration on first-line regimens (months)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 586</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;0&#x02013;30</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">1.71</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;31&#x02013;60</td><td align="center" valign="middle" rowspan="1" colspan="1">42</td><td align="center" valign="middle" rowspan="1" colspan="1">7.17</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;61&#x02013;90</td><td align="center" valign="middle" rowspan="1" colspan="1">124</td><td align="center" valign="middle" rowspan="1" colspan="1">21.16</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02265;91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">410</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.97</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Baseline CD4 at ART initiation (cell/mm<sup>3</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 548</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x0003c;200</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02265;200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">548</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CD4 at second-line initiation (cell/mm<sup>3</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 541</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x0003c;200</td><td align="center" valign="middle" rowspan="1" colspan="1">541</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02265;200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Current CD4 (during study (cell/mm<sup>3</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 555</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x0003c;200</td><td align="center" valign="middle" rowspan="1" colspan="1">161</td><td align="center" valign="middle" rowspan="1" colspan="1">29.00</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02265;200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">394</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Viral load (RNA copies/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 586</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x0003c;1000</td><td align="center" valign="middle" rowspan="1" colspan="1">505</td><td align="center" valign="middle" rowspan="1" colspan="1">86.18</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02265;1000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.82</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: antiretroviral (ARV), antiretroviral therapy (ART), abacavir (ABC), lamivudine (3TC), efavirenz (EFV), zidovudine (AZT), atazanavir/ritonavir (ATV/r), lopinavir/ritonavir (LPV/r), nevirapine (NVP), tenofovir (TDF), stavudine (D4T).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00206-t003"><object-id pub-id-type="pii">viruses-17-00206-t003_Table 3</object-id><label>Table 3</label><caption><p>Drug resistance mutation profiles among patients on second-line regimens with virological failure.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mutation Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic> (<italic toggle="yes">n</italic> = )</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Percent (%)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">NRTIs</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;A62V</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.86</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;D67N/G</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">8.57</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;E44ED</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">5.71</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;K65R</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">7.14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;K70E/G/R/T</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">8.57</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;L210W</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">4.29</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;L74I</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;M184V</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">22.86</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;K219E</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">7.14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;M41L</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.86</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;T215Y/V</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">10.00</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;T69SADN</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.86</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Y115F</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">8.57</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;S68G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.14</td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1">NNRTIs</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;A98G</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">7.55</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;E138A</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">3.77</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;G190A/E</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">13.21</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;H221Y</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">9.43</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;K101E/A</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">7.55</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;K103N</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">18.87</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;K238T</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.89</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;L100I</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">5.66</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;P225H</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.89</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;V106I/M</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">5.66</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;V108I</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">5.66</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;V179T/D</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">3.77</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Y181C</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">13.21</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Y188L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.89</td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1">PIs</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;I50L</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">11.76</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;I54V</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">23.53</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;L90M</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">5.88</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;M46I</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">23.53</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;N88S</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">5.88</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;V82A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.41</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00206-t004"><object-id pub-id-type="pii">viruses-17-00206-t004_Table 4</object-id><label>Table 4</label><caption><p>Multivariate analysis of factors associated with virological failure among patients on second-line ART.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">COR (95% CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AOR (95% CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Male</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53 (0.33&#x02013;0.85)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58 (0.32&#x02013;1.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Occupation </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Government employee </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Merchant </td><td align="center" valign="middle" rowspan="1" colspan="1">0.95 (0.40&#x02013;2.30)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.906</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 (0.44&#x02013;3.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.772</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Driver </td><td align="center" valign="middle" rowspan="1" colspan="1">1.93 (0.61&#x02013;6.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.265</td><td align="center" valign="middle" rowspan="1" colspan="1">2.10 (0.61&#x02013;7.20)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.243</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Housewife</td><td align="center" valign="middle" rowspan="1" colspan="1">0.60 (0.23&#x02013;1.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.285</td><td align="center" valign="middle" rowspan="1" colspan="1">1.02 (0.33&#x02013;3.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.973</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Student</td><td align="center" valign="middle" rowspan="1" colspan="1">4.13 (1.50&#x02013;11.40)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">6.14 (1.93&#x02013;19.48)</td><td align="center" valign="middle" rowspan="1" colspan="1"> 0.002 *</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Unemployed </td><td align="center" valign="middle" rowspan="1" colspan="1">1.35 (0.59&#x02013;3.10)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.478</td><td align="center" valign="middle" rowspan="1" colspan="1">1.67 (0.65&#x02013;4.31)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Other </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31 (0.62&#x02013;2.80)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.481</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.57 (0.67&#x02013;3.68)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.298</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Duration on ART at second-line (months)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x0003c;12</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref.</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x0003e;12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53 (0.30&#x02013;0.93)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.52 (0.28&#x02013;0.97)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.039 *</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Current CD4 (cell/mm<sup>3</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x0003c;200</td><td align="center" valign="middle" rowspan="1" colspan="1">2.55 (1.54&#x02013;4.21)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">2.55 (1.52&#x02013;4.28)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 *</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02265;200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AOR, adjusted odds ratios; COR, crude odds ratios; CI, confidence interval. (*) Statistically significant at <italic toggle="yes">p</italic> &#x02264; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00206-t005"><object-id pub-id-type="pii">viruses-17-00206-t005_Table 5</object-id><label>Table 5</label><caption><p>HIV drug resistance susceptibility test among the study participants (<italic toggle="yes">n</italic> = 37).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Resistance Level (<italic toggle="yes">n</italic> (%))</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiretroviral Drug</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Susceptible</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low Level of <break/>Resistance</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intermediate Level of Resistance</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High Level of <break/>Resistance</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">NRTIs</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Abacavir (ABC) </td><td align="center" valign="middle" rowspan="1" colspan="1">21 (56.78%) </td><td align="center" valign="middle" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (32.43%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Zidovudine (AZT)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (78.38%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (18.92%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Stavudine (D4T)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (59.46%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (8.11%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (8.11%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (24.32%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Didanosine (DDI)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (59.46%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (8.11%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (27.03%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Emtricitabine (FTC) </td><td align="center" valign="middle" rowspan="1" colspan="1">21 (56.76%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (43.24%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Lamivudine (3TC) </td><td align="center" valign="middle" rowspan="1" colspan="1">21 (56.76%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (43.24%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Tenofovir (TDF) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (62.16%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (16.22%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (16.22%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NNRTIs</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Doravirine (DOR)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (54.05%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (16.12%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (21.62%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (8.11%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Efavirenz (EFV) </td><td align="center" valign="middle" rowspan="1" colspan="1">13 (35.14%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (10.81%)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (48.65%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Etravirine (ETR)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (54.05%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (16.21%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (21.62%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (8.11%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Nevirapine (NVP) </td><td align="center" valign="middle" rowspan="1" colspan="1">13 (35.14%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (59.46%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Rilpivirine (RPV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (51.35%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (37.84%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PIs</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Atazanavir (ATV)</td><td align="center" valign="middle" rowspan="1" colspan="1">30 (81.08%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (16.22%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Darunavir (DRV)</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (100%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Fosamprenavir (FPV) </td><td align="center" valign="middle" rowspan="1" colspan="1">32 (86.49%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (5.41%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Indinavir (IDV) </td><td align="center" valign="middle" rowspan="1" colspan="1">31 (83.78%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (10.81%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Lopinavir (LPV) </td><td align="center" valign="middle" rowspan="1" colspan="1">31 (83.78%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (13.51%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Nelfinavir (NFV) </td><td align="center" valign="middle" rowspan="1" colspan="1">31 (83.78%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (13.51%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Saquinavir (SQV) </td><td align="center" valign="middle" rowspan="1" colspan="1">31 (83.78%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.70%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (10.81%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;Tipranavir (TPV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 (86.49%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (8.11%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (5.41%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap></floats-group></article>